搜索
Immune Technology 价格更新
发布时间：2022-06-12
mmune Technology（IT）专门从事病毒抗原和抗病毒抗体的研制和生产，用于诊断、监测和治疗重大病毒性传染病。此外，它提供许多定制服务，以满足您研究的具体需求。
mmune Technology（IT）专门从事病毒抗原和抗病毒抗体的研制和生产，用于诊断、监测和治疗重大病毒性传染病。此外，它提供许多定制服务，以满足您研究的具体需求。
| Immune Technology | IT-000-His-Biotin-0.05mg | Anti-6xHis tag | 6807.06 |
| Immune Technology | IT-000-His-M2-0.1mg | Anti-6xHis tag | 9404.28 |
| Immune Technology | IT-001-002M19-1mg | Anti- gp120/gp160(JRFL)(B)-1mg | 36864 |
| Immune Technology | IT-004-005M1-1mg | Anti- E2 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-005M2-1mg | Anti- E2 (HCV)-1mg | 42894.9 |
| Immune Technology | IT-004-005M3-1mg | Anti- E2 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M1-1mg | Anti-NS3 (HCV)-1mg | 42894.9 |
| Immune Technology | IT-004-011M10-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M11-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M12-1mg | Anti-NS3 (HCV)-1mg | 42894.9 |
| Immune Technology | IT-004-011M13-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M2-1mg | Anti-NS3 (HCV)-1mg | 42894.9 |
| Immune Technology | IT-004-011M3-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M4-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M5-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M6-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-011M7-1mg | Anti-NS3 (HCV)-1mg | 42894.9 |
| Immune Technology | IT-004-011M9-1mg | Anti-NS3 (HCV)-1mg | 36864 |
| Immune Technology | IT-004-013M1-1mg | Anti-NS5b (HCV)-1mg | 42894.9 |
| Immune Technology | IT-004-013M2-1mg | Anti-NS5b (HCV)-1mg | 36864 |
| Immune Technology | IT-004-013M3-1mg | Anti-NS5b (HCV)-1mg | 36864 |
| Immune Technology | IT-004-013M4-1mg | Anti-NS5b (HCV)-1mg | 36864 |
| Immune Technology | IT-004-013M5-1mg | Anti-NS5b (HCV)-1mg | 36864 |
| Immune Technology | IT-004-013M6-1mg | Anti-NS5b (HCV)-1mg | 36864 |
| Immune Technology | IT-004-013M7-1mg | Anti-NS5b (HCV)-1mg | 36864 |
| Immune Technology | IT-008-001-1ml | Anti-GP(Lassa Virus)-1ml | 24300 |
| Immune Technology | IT-200-001 | LecCapture | 4500 |
| Immune Technology | IT-200-003 | Blocking/Diluent Solution (concentrated) | 4482 |
| Immune Technology | IT-E3Ag-HIVgp120A-MAB | HIV-1 gp120 Clade A ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-HIVgp120B | HIV-1 gp120 Clade B ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-HIVgp120C-MAB | HIV-1 gp120 Clade C ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-HIVgp41CN54-MAB | gp41(HIV-1/Clade B/C(CN54)) ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ab-IgG(H7N9) | Antibody Detection Kit for H7N9 Hemagglutinin Specific Human IgG | 10782 |
| Immune Technology | IT-E3Ag-1976H1N1-New Jersey | HA(H1N1)(A/New Jersey/8/1976) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-1992H1N1-England | HA(H1N1)(A/Swine/England/WVL7/1992) Hemagglutinin ELISA Developmnet kit | 12546 |
| Immune Technology | IT-E3Ag-2007H1N1-Brisbane | HA(H1N1)(A/Brisbane/59/2007) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-2009H1N1 | 2009 H1N1 Influenza (A/Brisbane/59/2007) Hemagglutinin ELISA Kit | 12546 |
| Immune Technology | IT-E3Ag-2009H1N1-Beijing | HA(H1N1)(A/Beijing/01/2009) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-2009H1N1-Beijing/22808 | HA(H1N1)(A/Beijing/22808/2009) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-2009H1N1-California | HA(H1N1)(A/California/07/2009) Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-E3Ag-2009H1N1-California/06 | HA(H1N1)(A/California/06/2009) Hemagglutinin ELISA Development Kit . | 12546 |
| Immune Technology | IT-E3Ag-2009H1N1-New York | HA(H1N1)(A/New York/06/2009) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-2009H1N1-New York/6868 | HA(H1N1)(A/New York/6868/2009) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-2009H1N1-Texas | HA(H1N1)(A/Texas/05/2009) Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-E3Ag-H10N7-Blue-winged teal/LA/sg-00073/07 | HA(10N7)(A/Blue-winged teal/Louisiana/sg-00073/07) Antigen ELISA Development Kit | 12546 |
| Immune Technology | IT-E3Ag-H11N2-Duck/Yangzhou/906/2002 | HA(H11N2)(A/Duck/Yangzhou/906/2002) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H12N5-Green-winged teal/ALB/199/1991 | HA(H12N5)(A/Green-winged teal/ALB/199/1991) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H13N8-Black-headed gull/NL/1/00 | HA(H13N8)(A/Black-headed gull/Netherlands/1/00) Antigen ELISA Development Kit | 12546 |
| Immune Technology | IT-E3Ag-H14N5-Mallard/Astrakhan/263/1982 | HA(H14N5)(A/Mallard/Astrakhan/263/1982) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H15N8-Duck/Aus/341/1983 | HA(H15N8)(A/Duck/Aus/341/1983) Antigen ELISA Development Kit | 12546 |
| Immune Technology | IT-500-001Ep-0.1mg | MPT53 (M. Tuberculosis/CDC1551) | 7263.18 |
| Immune Technology | IT-500-002Ep-0.1mg | p60-Related Protein Rv0024 (M. Tuberculosis/H37Rv) | 7309.8 |
| Immune Technology | IT-E3Ag-H16N3-Black-headed gull/Sweden/5/99 | HA(H16N3)(A/Black-headed gull/Sweden/5/99) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-500-003Ep-0.1mg | Antigen Rv0192A (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H17N10-Little yellow-shouldered bet/GT/153 | HA(H17N10)(A/Little yellow-shouldered bet/Guatemala/153/2009) Antigen ELISA Development Kit | 12546 |
| Immune Technology | IT-500-004Ep-0.1mg | Antigen Rv2672 (M. Tuberculosis/H37Rv) | 7309.8 |
| Immune Technology | IT-E3Ag-H1N1 | 2009 H1N1 Influenza (Swine Flu) Hemagglutinin ELISA Kit | 12546 |
| Immune Technology | IT-500-005Ep-0.1mg | Antigen 85-C (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H1N1-New Caledonia/20/99 | HA(H1N1)(A/New Caledonia/20/99) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-500-006Ep-0.1mg | Antigen Rv0398c (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H1N1-South Caroline/1/18 | HA(H1N1)(A/South Carolina/1/18) Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-E3Ag-H2N2-Canada/720/05 | HA(H2N2)(A/Canada/720/05) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-500-007Ep-0.1mg | Antigen Rv2253 (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-500-008Ep-0.1mg | Antigen MT3413 (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H3-Pan | H3 Hemagglutinin Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H3N2-Brisbane/10/2007 | HA(H3N2)(A/Brisbane/10/2007) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-500-009Ep-0.1mg | Antigen Rv0477 (M. Tuberculosis/H37Rv) | 7309.8 |
| Immune Technology | IT-500-010Ep-0.1mg | Antigen Mpt63/MPB63 (M. Tuberculosis/H37Rv) | 7309.8 |
| Immune Technology | IT-E3Ag-H3N2-Perth/16/2009 | HA(H3N2)(A/Perth/16/2009) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H3N2-Sydney/5/97 | HA(H3N2)(A/Sydney/5/97) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-500-011Ep-0.1mg | Antigen 85-A (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-500-012Ep-0.1mg | Antigen Mpt70 (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H3N2-Wisconsin/67/X-161/2005 | HA(H3N2)(A/Wisconsin/67/X-161/2005) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H3N2-Wyoming/3/03 | HA(H3N2)(A/Wyoming/3/03) Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-500-013Ep-0.1mg | Antigen MPT83 (M. Tuberculosis/H37Rv) | 7309.8 |
| Immune Technology | IT-500-014Ep-0.1mg | Antigen Mpt64 (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H4N6-Swine/Ontario/01911-1/99 | HA(H4N6)(A/Swine/Ontario/01911-1/99) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H5N1-Anhui/1/2005 | HA(H5N1)(A/Anhui/1/2005) Hemagglutinin ELISA Development Kit | 13383.72 |
| Immune Technology | IT-500-015Ep-0.1mg | Antigen 85-B (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-500-016Ep-0.1mg | Antigen TB22.2 (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H5N1-Chicken/India/NIV3348/2006 | HA(H5N1)(A/Chicken/India/NIV3348/2006) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-H5N1-CM/HK/2256/2006 | HA(H5N1)(A/CM/HK/2256/2006) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-500-017Ep-0.1mg | Antigen ESAT-6 (M. Tuberculosis/H37Rv) | 7309.8 |
| Immune Technology | IT-500-018Ep-0.1mg | Antigen EsxB (LHP) (CFP10)(M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H5N1-Egypt/chicken/2253-1/2006 | HA(H5N1)(A/Egypt/chicken/2253-1/2006) Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-E3Ag-H5N1-goose/Guiyang/337/2006 | HA(H5N1)(A/goose/Guiyang/337/2006) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-500-019Ep-0.1mg | Antigen TB15.3 (M. Tuberculosis/CDC1551) | 6282 |
| Immune Technology | IT-500-020Ep-0.1mg | EspC/Rv3615c (M. Tuberculosis/H37Rv) | 6282 |
| Immune Technology | IT-E3Ag-H5N1-Indonesia/5/2005 | HA(H5N1)(A/Indonesia/5/2005) Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-E3Ag-H5N1-JP white-eye/HK/1038/2006 | HA(H5N1)(A/JP white-eye/HK/1038/2006) Hemagglutinin ELISA Develo | 10782 |
| Immune Technology | IT-501-003Ep-0.1mg | TA34_TREPA (T. pallidum/Nichols strain) | 7309.8 |
| Immune Technology | IT-E3Ag-H6N1-NS/Calif/H1CWF115/2007 | HA(H6N1)(A/Northern shoveler/California/H1CWF115/2007) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-501-004Ep-0.1mg | p47 (T. pallidum/Nichols strain) | 7309.8 |
| Immune Technology | IT-E3Ag-H7(Eurasia)-Pan | H7(Eurasia)(Pan) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-501-005Ep-0.1mg | TmpA (T. pallidum/Nichols strain) | 7309.8 |
| Immune Technology | IT-501-006Ep-0.1mg | TPN50_TREPA (T. pallidum/Nichols strain) | 6282 |
| Immune Technology | IT-501-007Ep-0.1mg | TP453_TREPA (T. pallidum/Nichols strain) | 7309.8 |
| Immune Technology | IT-501-009Ep-0.1mg | TmpB (T. pallidum/Nichols strain) | 6282 |
| Immune Technology | IT-501-010Ep-0.1mg | tpn39b (T. pallidum/Nichols strain) | 7309.8 |
| Immune Technology | IT-E3Ag-H7-Pan | H7(Pan) Antigens Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-502-001Ep-0.1mg | MOMP (C. trachomatis strain D/UW-3/CX Serovar D) | 6282 |
| Immune Technology | IT-501-011Ep-0.1mg | TpN32 (T. pallidum/Nichols strain) | 6282 |
| Immune Technology | IT-E3Ag-H8N4-Pintail duck/Alberta/114/1979 | HA(H8N4)(A/Pintail duck/Alberta/114/1979) Antigen ELISA Development Kit | 10782 |
| Immune Technology | IT-502-002Ep-0.1mg | MOMP (C. trachomatis strain C/TW-3 Serovar C) | 6282 |
| Immune Technology | IT-E3Ag-H9-Pan | H9 Antigens Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-502-003Ep-0.1mg | MOMP (C. trachomatis strain 404 Serovar L3) | 6282 |
| Immune Technology | IT-E3Ag-H9N2-HK/33982/2009 | HA(H9N2)(A/HK/33982/2009) Hemagglutinin ELISA Development Kit | 10782 |
| Immune Technology | IT-502-004Ep-0.1mg | MOMP (C. trachomatis strain B/Tw-5/OT Serovar B) | 7309.8 |
| Immune Technology | IT-502-005Ep-0.1mg | MOMP (C. trachomatis strain SA1/OT / Serovar A) | 6282 |
| Immune Technology | IT-503-001Ep-0.1mg | P30C adhesin (Mycoplasma pneumoniae M129) | 7309.8 |
| Immune Technology | IT-E3Ag-Influenza (B/HA)-Pan | Influenza B (Pan) Hemagglutinin ELISA Development Kit | 12546 |
| Immune Technology | IT-503-003Ep-0.1mg | P1-IV adhesin (Mycoplasma pneumoniae M129) | 6282 |
| Immune Technology | IT-E3Ag-M1(H1N1)(A/PR8/34) | M1(H1N1)(A/PR8/34) ELISA Development Kit | 10782 |
| Immune Technology | IT-503-004Ep-0.1mg | P116 (Mycoplasma pneumoniae M129) | 6282 |
| Immune Technology | IT-503-015Ep-0.1mg | MB (Ureaplasma urealyticum) | 6282 |
| Immune Technology | IT-E3Ag-M1(H1N1)(Influenza A) | M1(H1N1)(Influenza A) ELISA Development Kit | 10782 |
| Immune Technology | IT-503-016Ep-0.1mg | MB (Ureaplasma parvum/serovar 1) | 7309.8 |
| Immune Technology | IT-E3Ag-M1(H3N2)(Influenza A) | M1(H3N2)(Influenza A) ELISA Development Kit | 10782 |
| Immune Technology | IT-000- Pfu-×1000 Units | Pfu DNA polymerase | 6282 |
| Immune Technology | IT-000-SUMOProt-0.1ml | SUMO protease | 7309.8 |
| Immune Technology | IT-E3Ag-NP(Influenza A) | NP(Influenza A) ELISA Development Kit | 10782 |
| Immune Technology | IT-E3Ag-NS1(DV2) | NS1(DV2) ELISA Development Kit | 10782 |
| Immune Technology | IT-000-PNGF2-0.1ml | PNGase F-II | 5670 |
| Immune Technology | IT-E3Ag-NS1(DV4) | NS1(DV4) ELISA Development Kit | 10782 |
| Immune Technology | IT-000-proK-1ml | Proteinase K | 3665.34 |
| Immune Technology | IT-001-0011p-0.1mg | gp140(Clade A) | 8982 |
| Immune Technology | IT-001-0012p-0.1mg | gp120 (Q769.h5)(Clade A) | 8982 |
| Immune Technology | IT-001-001p-0.1mg | gp120(92RW020)(Clade A) | 8982 |
| Immune Technology | IT-001-0021p-0.1mg | gp140(Clade B) | 8982 |
| Immune Technology | IT-E3Ag-NS1(JEV) | NS1(JEV) ELISA Development Kit | 10782 |
| Immune Technology | IT-001-0022p-0.1mg | gp120(HXBc2)(CladeB) | 10451.52 |
| Immune Technology | IT-001-0023p-0.1mg | gp120(ADA)(CladeB) | 8982 |
| Immune Technology | IT-001-0024∆TMp-0.1mg | gp140(JRFL)(HIV-1/Clade B) | 10451.52 |
| Immune Technology | IT-E3Ag-NS1(Zika Virus)-1 | NS1 (Zika Virus) ELISA Development Kit | 10782 |
| Immune Technology | IT-001-0024p-0.1mg | gp120(JRFL)(HIV-1) | 8982 |
| Immune Technology | IT-001-0025p-0.1mg | gp120(JRCSF)(HIV-1/Clade B) | 8982 |
| Immune Technology | IT-E3Ag-NP (Schmallenberg Virus) | Schmallenberg Virus Nucleoprotein (NP) ELISA Development Kit | 12546 |
| Immune Technology | IT-001-0026p-0.1mg | gp120(89.6P)(HIV-1) | 8982 |
| Immune Technology | IT-001-0027p-0.1mg | gp120(YU2)(HIV-1) | 8982 |
| Immune Technology | IT-E3Ag-NP(RVFV) | NP (Rift Valley Fever Virus) ELISA Development Kit | 10782 |
| Immune Technology | IT-001-0028p-0.1mg | gp120(SF162)(Clade B) | 8982 |
| Immune Technology | IT-001-0029p-0.1mg | gp120(R2)(Clade B) | 8982 |
| Immune Technology | IT-200-010 | HRP-Goat anti-Mouse IgG(H+L) | 5184 |
| Immune Technology | IT-001-002MNp-0.1mg | gp120(MN)(HIV-1/Clade B) | 8982 |
| Immune Technology | IT-200-011 | HRP-Goat anti-Rabbit IgG(H+L) | 6032.16 |
| Immune Technology | IT-001-002p-0.1mg | gp120 (Bal)(Clade B) | 8982 |
| Immune Technology | IT-001-0031p-0.1mg | gp140 (Clade C) | 8982 |
| Immune Technology | IT-001-003CNp-0.1mg | gp120 (CN54) | 10451.52 |
| Immune Technology | IT-001-003p-0.1mg | gp120 (Clade C) | 8982 |
| Immune Technology | IT-200-012 | HRP-Goat anti-Human IgG(H+L) | 5904 |
| Immune Technology | IT-001-0051p | gp41(∆TM)(Bal) | 0 |
| Immune Technology | IT-001-0052p-0.1mg | gp41(Ectodomain)(HIV-1) | 8982 |
| Immune Technology | IT-100-001 | 293-IS™ Transfection Reagent | 5382 |
| Immune Technology | IT-001-005p-0.1mg | gp41 (HXBc2) | 8982 |
| Immune Technology | IT-001-007Ep-0.1mg | Gag (HIV-1/Clade A) | 6282 |
| Immune Technology | IT-001-008Ep-0.1mg | Gag (HIV-1/Clade B) | 7309.8 |
| Immune Technology | IT-100-001-1 | 293-IS™ Expression Enhancer-1 | 4464 |
| Immune Technology | IT-001-009Ep-0.1mg | Gag (HIV-1/Clade C) | 7263.18 |
| Immune Technology | IT-001-010Ep-0.1mg | p17 (HIV-1/Clade A) | 6282 |
| Immune Technology | IT-001-011Ep-0.1mg | p17 (HIV-1/Clade C) | 6282 |
| Immune Technology | IT-001-012Ep-0.1mg | p17 (HIV-1/HXBc2) | 6282 |
| Immune Technology | IT-001-013Ep-0.1mg | Nef (HIV-1/clade A) | 7309.8 |
| Immune Technology | IT-001-014Ep-0.1mg | Nef (HIV-1/Clade B) | 7263.18 |
| Immune Technology | IT-001-015Ep-0.1mg | Nef (HIV-1/Clade C) | 6282 |
| Immune Technology | IT-001-016Ep-0.1mg | p24 (HIV-1/Clade A) | 7309.8 |
| Immune Technology | IT-001-017Ep-0.1mg | p24 (HIV-1/Clade B)(HXBc2) | 6282 |
| Immune Technology | IT-001-017p-0.1mg | p24 (HXBc2) | 8982 |
| Immune Technology | IT-001-018Ep-0.1mg | p27 (SIV/mac239) | 7263.18 |
| Immune Technology | IT-001-018p-0.1mg | p27(SIV/mac239) | 10451.52 |
| Immune Technology | IT-001-019Ep-0.1mg | p24 (HIV-1/Clade C) | 6282 |
| Immune Technology | IT-001-020Ep-0.1mg | p24(HIV-1/Clade B/C(CN54)) | 6282 |
| Immune Technology | IT-001-020p-0.1mg | p24(HIV-1/Clade B/C(CN54)) | 8982 |
| Immune Technology | IT-001-021p-0.1mg | p24 Capsid Protein (HIV-1/Clade A)(Q23-CxC) | 8982 |
| Immune Technology | IT-001-022p-0.1mg | gp120(SIV/mac239) | 8982 |
| Immune Technology | IT-001-022p-Biotin-0.05mg | Biotinylated gp120 (SIV/mac239) | 8303.76 |
| Immune Technology | IT-001-024Ep-0.1mg | Gag (SIV-1/mac239) | 7309.8 |
| Immune Technology | IT-001-026Ep-0.1mg | Nef (SIV-1/mac239) | 6282 |
| Immune Technology | IT-001-027Ep-0.1mg | Nef (SIV-1/mac251) | 6282 |
| Immune Technology | IT-001-101p-0.1mg | gp120(MG505.W0M.ENV.A2)(Clade A) | 8982 |
| Immune Technology | IT-001-102p-0.1mg | gp120(MG505.W0M.ENV.H3)(Clade A) | 10384.92 |
| Immune Technology | IT-001-103p-0.1mg | gp120(MF535.W0M.ENV.D11)(Clade A) | 8982 |
| Immune Technology | IT-001-105p-0.1mg | gp120(MI206.W0M.ENV.B1)(Clade A) | 8982 |
| Immune Technology | IT-001-106p-0.1mg | gp120(MI206.W0M.ENV.D1)(Clade A) | 10451.52 |
| Immune Technology | IT-001-107p-0.1mg | gp120(MJ412.W0M.ENV.B1)(Clade A) | 8982 |
| Immune Technology | IT-001-108p-0.1mg | gp120(MJ412.W0M.ENV.C1)(Clade A) | 10451.52 |
| Immune Technology | IT-001-109p-0.1mg | gp120(MJ613.W0M.ENV.A2)(Clade A) | 10384.92 |
| Immune Technology | IT-001-110p-0.1mg | gp120(MJ613.W0M.ENV.B1)(Clade A) | 10384.92 |
| Immune Technology | IT-001-111p-0.1mg | gp120(MK184.W0M,ENV.E4)(Clade A) | 10384.92 |
| Immune Technology | IT-001-112p-0.1mg | gp120(MK184.W0M,ENV.G3)(Clade A) | 10451.52 |
| Immune Technology | IT-001-113p-0.1mg | gp120(ML035.W0M.ENV.G2)(Clade A) | 10451.52 |
| Immune Technology | IT-001-114p-0.1mg | gp120(ML035.W0M.ENV.I2)(Clade A) | 10384.92 |
| Immune Technology | IT-001-115p-0.1mg | gp120(BL035.W6M.ENV.C1)(Clade A) | 8982 |
| Immune Technology | IT-001-116p-0.1mg | gp120(ML274.W0M.ENV.B1)(Clade A) | 8982 |
| Immune Technology | IT-001-117p-0.1mg | gp120(ML274.W0M.ENV.F1)(Clade A) | 8982 |
| Immune Technology | IT-001-118p-0.1mg | gp120(BL274.W6M.ENV.A3)(Clade A) | 8982 |
| Immune Technology | IT-001-119p-0.1mg | gp120(p1012.TC21.3257)(Clade B) | 10384.92 |
| Immune Technology | IT-001-120p-0.1mg | gp120(p1006_11.C3.1601)(Clade B) | 8982 |
| Immune Technology | IT-001-121p-0.1mg | gp120(p1054.TC4.1499)(Clade B) | 8982 |
| Immune Technology | IT-001-122p-0.1mg | gp120(p1056.TA11.1826)(Clade B) | 8982 |
| Immune Technology | IT-001-123p-0.1mg | gp120(p1058_11.B11.1550)(Clade B) | 8982 |
| Immune Technology | IT-001-124p-0.1mg | gp120(p1059_09.A4.1460)(Clade B) | 10451.52 |
| Immune Technology | IT-001-125p-0.1mg | gp120(p62357_14.D3.4589)(Clade B) | 10451.52 |
| Immune Technology | IT-001-126p-0.1mg | gp120(p6240_08.TA5.4622)(Clade B) | 8982 |
| Immune Technology | IT-001-127p-0.1mg | gp120(p6244_13.B5.4576)(Clade B) | 10451.52 |
| Immune Technology | IT-001-128p-0.1mg | gp120(p63358.p3.4013)(Clade B) | 8982 |
| Immune Technology | IT-001-129p-0.1mg | gp120(p700010040.C9.4520)(Clade B) | 10451.52 |
| Immune Technology | IT-001-130p-0.1mg | gp120(p700010058.A4.4357)(Clade B) | 8982 |
| Immune Technology | IT-001-131p-0.1mg | gp120(p9014_01.TB1.4769)(Clade B) | 8982 |
| Immune Technology | IT-001-132p-0.1mg | gp120(p9021_14.B2.4571)(Clade B) | 8982 |
| Immune Technology | IT-001-133p-0.1mg | gp120(pPRB926_04.A9.4239)(Clade B) | 8982 |
| Immune Technology | IT-001-134p-0.1mg | gp120(pPRB931_06.TC3.4930)(Clade B) | 8982 |
| Immune Technology | IT-001-135p-0.1mg | gp120(pSC05.8C11.2344)(Clade B) | 8982 |
| Immune Technology | IT-001-136p-0.1mg | gp120(pSC45.4B5.2631)(Clade B) | 8982 |
| Immune Technology | IT-001-137p-0.1mg | gp120(pWEAUd15.410.5017)(Clade B) | 10451.52 |
| Immune Technology | IT-001-138∆TMp-0.1mg | gp140(HIV-1/LAI)(Clade B) | 10451.52 |
| Immune Technology | IT-001-138p-0.1mg | gp120(LAI)(Clade B) | 10451.52 |
| Immune Technology | IT-001-139p-0.1mg | gp120(Du151)(Clade C) | 10451.52 |
| Immune Technology | IT-001-139p-Biotin-0.05mg | Biotinylated gp120(Du151)(HIV-1/Clade C) | 8357.04 |
| Immune Technology | IT-001-140p-0.1mg | gp140(mac239)(SIV) | 8982 |
| Immune Technology | IT-001-140p-Biotin-0.05mg | Biotinylated gp140 (SIV/mac239) | 8357.04 |
| Immune Technology | IT-001-141p-0.1mg | gp140(SIVsmE660) | 10451.52 |
| Immune Technology | IT-001-141p-Biotin-0.05mg | Biotinylated gp140(SIVsmE660) | 8303.76 |
| Immune Technology | IT-001-142p-0.1mg | gp120(SIVsmE660) | 8982 |
| Immune Technology | IT-001-142p-Biotin-0.05mg | Biotinylated gp120(SIVsmE660) | 7182 |
| Immune Technology | IT-001-143p-Enquiry | gp140(SF162)(HIV-1) | 2700 |
| Immune Technology | IT-001-145p-0.05mg | gp140(SHIV SF162P3)(HIV-1) | 8082 |
| Immune Technology | IT-001-146p-0.1mg | gp120(SHIV SF162P3)(HIV-1) | 8982 |
| Immune Technology | IT-001-147p-0.1mg | gp120(smE543)(SIV) | 8982 |
| Immune Technology | IT-001-148p-0.05mg | gp140(smE543)(SIV) | 8082 |
| Immune Technology | IT-001-149p-0.1mg | gp120(00KE_KER2018)(HIV-1/Clade A) | 8982 |
| Immune Technology | IT-001-150p-0.1mg | gp120(CM235/CRF01_AE)(HIV-1) | 10451.52 |
| Immune Technology | IT-001-151p-0.1mg | gp120(HIV-1/Clade 01_AE/CM240) | 8982 |
| Immune Technology | IT-001-152p-0.1mg | gp120(HIV-1/Clade 01_AE/90TH_CM244) | 8982 |
| Immune Technology | IT-500-001Ep-1mg | MPT53 (M. Tuberculosis/CDC1551) 1mg | 26160.12 |
| Immune Technology | IT-500-002Ep-1mg | p60-Related Protein Rv0024 (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-153p-0.1mg | gp120(HIV-1/Clade CRF02_AG/98US_MSC5007) | 8982 |
| Immune Technology | IT-001-154p-0.1mg | gp120(HIV-1/Clade CRF02_AG/ 01CM_0002BBY | 8982 |
| Immune Technology | IT-500-003Ep-1mg | Antigen Rv0192A (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-500-004Ep-1mg | Antigen Rv2672 (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-155p-0.1mg | gp120(HIV-1/Clade CRF02_AG/01CM_1475MV) | 8982 |
| Immune Technology | IT-001-156FRp-0.1mg | gp120(SIV/mac251)(Mucosal Funder Strain 216.94.A2) | 10451.52 |
| Immune Technology | IT-500-005Ep-1mg | Antigen 85-C (M. Tuberculosis/H37Rv) 1mg | 26160.12 |
| Immune Technology | IT-500-006Ep-1mg | Antigen Rv0398c (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-156FVp-0.1mg | gp120(SIV/mac251)(Mucosal Funder Strain SIVmac251v31523ru28) | 10451.52 |
| Immune Technology | IT-500-007Ep-1mg | Antigen Rv2253 (M. Tuberculosis/H37Rv) 1mg | 26160.12 |
| Immune Technology | IT-001-156p-0.1mg | gp120(mac251)(SIV) | 8982 |
| Immune Technology | IT-001-157p-0.1mg | gp120(SIVcpz EK505) | 8982 |
| Immune Technology | IT-500-008Ep-1mg | Antigen MT3413 (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-158p-0.1mg | gp120(SIVcpz MB66) | 8982 |
| Immune Technology | IT-500-009Ep-1mg | Antigen Rv0477 (M. Tuberculosis/H37Rv) 1mg | 26160.12 |
| Immune Technology | IT-001-159p-Enquiry | gp140(Du151)(HIV-1/Clade C) | 2700 |
| Immune Technology | IT-500-010Ep-1mg | Antigen Mpt63/MPB63 (M. Tuberculosis/H37Rv) 1mg | 26160.12 |
| Immune Technology | IT-001-160p-0.1mg | gp120(HIV-1/Clade B/C(CN54)) | 10451.52 |
| Immune Technology | IT-500-011Ep-1mg | Antigen 85-A (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-161p-0.1mg | gp140(HIV-1/Clade B/C(CN54)) | 8982 |
| Immune Technology | IT-001-161p-Biotin-0.05mg | Biotinylated gp140(HIV-1/Clade B’/C(CN54)) | 7182 |
| Immune Technology | IT-500-012Ep-1mg | Antigen Mpt70 (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-162p-0.1mg | gp140(HIV-1/Clade B/C)(Consensus) | 10451.52 |
| Immune Technology | IT-001-163p-0.1mg | gp120(HIV-1/Clade B/C)(Consensus) | 8982 |
| Immune Technology | IT-500-013Ep-1mg | Antigen MPT83 (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-500-014Ep-1mg | Antigen Mpt64 (M. Tuberculosis/H37Rv) 1mg | 26160.12 |
| Immune Technology | IT-001-164p-0.1mg | gp120(HIV-1/Clade AE)(A244) | 8982 |
| Immune Technology | IT-001-165p-0.1mg | gp140(HIV-1/Clade AE)(A244) | 8982 |
| Immune Technology | IT-500-015Ep-1mg | Antigen 85-B (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-500-016Ep-1mg | Antigen TB22.2 (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-166p-0.1mg | gp120(CH181)(CRF07_BC) | 8982 |
| Immune Technology | IT-001-167p-0.1mg | gp140(HIV-1/Clade AE)(Consensus) | 10451.52 |
| Immune Technology | IT-001-168p-0.1mg | gp120(HIV-1/Clade AE)(Consensus) | 8982 |
| Immune Technology | IT-500-017Ep-1mg | Antigen ESAT-6 (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-169p-0.1mg | gp140(TV-1)(HIV-1/Clade C) | 8982 |
| Immune Technology | IT-500-018Ep-1mg | Antigen EsxB (LHP) (CFP10)(M. Tuberculosis/H37Rv) 1mg | 26160.12 |
| Immune Technology | IT-500-019Ep-1mg | Antigen TB15.3 (M. Tuberculosis/CDC1551) 1mg | 22482 |
| Immune Technology | IT-500-020Ep-1mg | EspC/Rv3615c (M. Tuberculosis/H37Rv) 1mg | 22482 |
| Immune Technology | IT-001-171p-0.1mg | gp140(BL10)(HIV-1/Clade B) | 10451.52 |
| Immune Technology | IT-001-172p-0.1mg | gp120(BL10)(HIV-1/Clade B) | 8982 |
| Immune Technology | IT-001-173ΔTMp-Enquiry | gp140(HIV-1/Bal.01)(Clade B) | 3141.72 |
| Immune Technology | IT-001-174p-0.1mg | gp120 (001428-2.4)(Clade C) | 8982 |
| Immune Technology | IT-501-002Ep-1mg | tpp17 (T. pallidum/Nichols strain) 1mg | 22482 |
| Immune Technology | IT-501-003Ep-1mg | TA34_TREPA (T. pallidum/Nichols strain) 1mg | 22482 |
| Immune Technology | IT-001-175p-0.1mg | gp120(Q461.d1)(Clade A) | 8982 |
| Immune Technology | IT-501-004Ep-1mg | p47 (T. pallidum/Nichols strain) 1mg | 22482 |
| Immune Technology | IT-501-005Ep-1mg | TmpA (T. pallidum/Nichols strain) 1mg | 22482 |
| Immune Technology | IT-001-176p-0.1mg | gp120(BG505.W6M.ENV.C1)(Clade A) | 8982 |
| Immune Technology | IT-501-006Ep-1mg | TPN50_TREPA (T. pallidum/Nichols strain) 1mg | 26160.12 |
| Immune Technology | IT-501-007Ep-1mg | TP453_TREPA (T. pallidum/Nichols strain) 1mg | 26160.12 |
| Immune Technology | IT-001-177p-0.1mg | gp120(BG505.W6M.ENV.C1.A204E) (Clade A) | 10451.52 |
| Immune Technology | IT-001-178p-0.1mg | gp120(QA255.21P.ENV.A17)(Clade A) | 8982 |
| Immune Technology | IT-501-009Ep-1mg | TmpB (T. pallidum/Nichols strain) 1mg | 26160.12 |
| Immune Technology | IT-501-010Ep-1mg | tpn39b (T. pallidum/Nichols strain) 1mg | 26160.12 |
| Immune Technology | IT-001-179p-0.1mg | gp120 (BF520.M6P.D1)(Clade A) | 8982 |
| Immune Technology | IT-001-191p-0.1mg | gp120 (C2-94UG114)(HIV-1/Clade D) | 10451.52 |
| Immune Technology | IT-501-011Ep-1mg | TpN32 (T. pallidum/Nichols strain) 1mg | 22482 |
| Immune Technology | IT-502-001Ep-1mg | MOMP (C. trachomatis strain D/UW-3/CX Serovar D) 1mg | 22482 |
| Immune Technology | IT-001-201p-0.1mg | gp120(HIV-2/Ben) | 8982 |
| Immune Technology | IT-502-002Ep-1mg | MOMP (C. trachomatis strain C/TW-3 Serovar C) 1mg | 26160.12 |
| Immune Technology | IT-502-003Ep-1mg | MOMP (C. trachomatis strain 404 Serovar L3) 1mg | 22482 |
| Immune Technology | IT-001-202p-0.1mg | gp120(HIV-2/NIH-Z) | 8982 |
| Immune Technology | IT-502-004Ep-1mg | MOMP (C. trachomatis strain B/Tw-5/OT Serovar B) 1mg | 22482 |
| Immune Technology | IT-502-005Ep-1mg | MOMP (C. trachomatis strain SA1/OT / Serovar A) 1mg | 22482 |
| Immune Technology | IT-001-203p-0.1mg | gp120(HIV-2/B_UC1) | 10451.52 |
| Immune Technology | IT-503-001Ep-1mg | P30C adhesin (Mycoplasma pneumoniae M129) 1mg | 22482 |
| Immune Technology | IT-503-003Ep-1mg | P1-IV adhesin (Mycoplasma pneumoniae M129) 1mg | 22482 |
| Immune Technology | IT-503-004Ep-1mg | P116 (Mycoplasma pneumoniae M129) 1mg | 22482 |
| Immune Technology | IT-001-211p-0.05mg | gp70(MLV)-V1V2(HIV-1/CN54) | 11498.76 |
| Immune Technology | IT-001-212p-0.1mg | gp70(MLV)-V1V2(HIV-1/AE/A244) | 10384.92 |
| Immune Technology | IT-503-015Ep-1mg | MB (Ureaplasma urealyticum) 1mg | 22482 |
| Immune Technology | IT-503-016Ep-1mg | MB (Ureaplasma parvum/serovar 1) 1mg | 22482 |
| Immune Technology | IT-000-SUMOProt-0.5ml | SUMO protease 0.5ml | 17082 |
| Immune Technology | IT-001-213p-Enquiry | gp70(MLV)-V1V2(HIV-1/Consensus_C) | 3141.72 |
| Immune Technology | IT-001-214p-0.05mg | gp70(MLV)-V1V2(HIV-1/Clade B/Case A2) | 9404.28 |
| Immune Technology | IT-000-proK-100mg | Proteinase K 100mg | 3600 |
| Immune Technology | IT-001-0011p-1mg | gp140(Clade A) 1mg | 57402 |
| Immune Technology | IT-001-0012p-1mg | gp120 (Q769.h5)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-001-317p-0.1mg | hCD317(ΔTMs) | 8982 |
| Immune Technology | IT-001-001p-1mg | gp120(92RW020)(Clade A) 1mg | 57402 |
| Immune Technology | IT-001-0021p-1mg | gp140(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-001-0022p-1mg | gp120(HXBc2)(CladeB) 1mg | 57402 |
| Immune Technology | IT-001-0023p-1mg | gp120(ADA)(CladeB) 1mg | 57402 |
| Immune Technology | IT-001-CD4d1d2p-0.1mg | Human CD4(D1D2 region) | 8982 |
| Immune Technology | IT-001-0024∆TMp-1mg | gp140(JRFL)(HIV-1/Clade B) 1mg | 57402 |
| Immune Technology | IT-001-CD4p-0.1mg | hCD4(Ectodomain) | 8982 |
| Immune Technology | IT-001-0024p-1mg | gp120(JRFL)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-001-0025p-1mg | gp120(JRCSF)(HIV-1/Clade B) 1mg | 66792.96 |
| Immune Technology | IT-001-CD4p-Biotin-0.05mg | Biotinylated hCD4(Ectodomain) | 7182 |
| Immune Technology | IT-001-CD4p-FITC-0.05mg | FITC-labeled hCD4(Ectodomain) | 7164 |
| Immune Technology | IT-001-0026p-1mg | gp120(89.6P)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-001-0027p-1mg | gp120(YU2)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-001-CONA1p-0.1mg | gp120(Con_A1) | 10451.52 |
| Immune Technology | IT-001-CONA2p-0.1mg | gp120(Con_A2) | 10451.52 |
| Immune Technology | IT-001-CONBp-0.1mg | gp120(Con_B) | 10451.52 |
| Immune Technology | IT-001-0028p-1mg | gp120(SF162)(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-001-CONCp-0.1mg | gp120(Con_C)(HIV-1) | 8982 |
| Immune Technology | IT-001-CONp-0.1mg | gp120(Con of Cons) | 8982 |
| Immune Technology | IT-001-0029p-1mg | gp120(R2)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-002MNp-1mg | gp120(MN)(HIV-1/Clade B) 1mg | 57402 |
| Immune Technology | IT-001-RB10p-0.1mg | gp120(pTHRO4156)(Clade B) | 10451.52 |
| Immune Technology | IT-001-RB11p-0.1mg | gp120(pCAAN5342) | 8982 |
| Immune Technology | IT-001-RB12p-0.1mg | gp120(SC422661.8)(CladeB) | 8982 |
| Immune Technology | IT-001-RB1p-0.1mg | gp120(6535)(HIV-1) | 10451.52 |
| Immune Technology | IT-001-RB2p-0.1mg | gp120(QH0692) | 8982 |
| Immune Technology | IT-001-002p-1mg | gp120 (Bal)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-RB3p-0.1mg | gp120(PVO) | 8982 |
| Immune Technology | IT-001-0031p-1mg | gp140 (Clade C) 1mg | 57402 |
| Immune Technology | IT-001-RB4p-0.1mg | gp120(TRO)(Clade B) | 8982 |
| Immune Technology | IT-001-003CNp-1mg | gp120 (CN54) 1mg | 57402 |
| Immune Technology | IT-001-003p-1mg | gp120 (Clade C) 1mg | 57402 |
| Immune Technology | IT-001-RB5p-0.1mg | gp120(AC10.0)(HIV-1) | 8982 |
| Immune Technology | IT-001-0052p-1mg | gp41(Ectodomain)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-001-007Ep-1mg | Gag (HIV-1/Clade A) 1mg | 26160.12 |
| Immune Technology | IT-001-RB6p-0.1mg | gp120(pWITO4160) | 8982 |
| Immune Technology | IT-001-008Ep-1mg | Gag (HIV-1/Clade B) 1mg | 22482 |
| Immune Technology | IT-001-RB7p-0.1mg | gp120(pTRJO4551)(Clade B) | 8982 |
| Immune Technology | IT-001-RB8p-0.1mg | gp120(pREJO4541) | 8982 |
| Immune Technology | IT-001-009Ep-1mg | Gag (HIV-1/Clade C) 1mg | 26160.12 |
| Immune Technology | IT-001-RB9p-0.1mg | gp120(pRHPA4259) | 8982 |
| Immune Technology | IT-001-RC10p-0.1mg | gp120(ZM135M.PL10a)(HIV-1) | 8982 |
| Immune Technology | IT-001-RC11p-0.1mg | gp120(CAP45.2.00) | 8982 |
| Immune Technology | IT-001-010Ep-1mg | p17 (HIV-1/Clade A) 1mg | 26160.12 |
| Immune Technology | IT-001-RC12p-0.1mg | gp120(CAP210.2.00)(Clade C) | 10451.52 |
| Immune Technology | IT-001-011Ep-1mg | p17 (HIV-1/Clade C) 1mg | 26160.12 |
| Immune Technology | IT-001-RC1p-0.1mg | gp120(Du156.12)(Clade C) | 10451.52 |
| Immune Technology | IT-001-RC2p-0.1mg | gp120(Du172.17)(Clade C) | 8982 |
| Immune Technology | IT-001-RC3p-0.1mg | gp120(Du422.1)(Clade C) | 8982 |
| Immune Technology | IT-001-RC4p-0.1mg | gp120(ZM197M.PB7) (Clade C) | 10451.52 |
| Immune Technology | IT-001-012Ep-1mg | p17 (HIV-1/HXBc2) 1mg | 22482 |
| Immune Technology | IT-001-RC5p-0.1mg | gp120(ZM214M.PL15) (Clade C) | 8982 |
| Immune Technology | IT-001-013Ep-1mg | Nef (HIV-1/clade A) 1mg | 22482 |
| Immune Technology | IT-001-RC6p-0.1mg | gp120(ZM233M.PB6) (Clade C) | 8982 |
| Immune Technology | IT-001-RC7p-0.1mg | gp120(ZM249M.PL1)(Clade C) | 10451.52 |
| Immune Technology | IT-001-RC8p-0.1mg | gp120(ZM53M.PB12)(Clade C) | 10451.52 |
| Immune Technology | IT-001-RC9p-0.1mg | gp120(ZM109F.PB4) (Clade C) | 8982 |
| Immune Technology | IT-001-rhCD4-0.1mg | CD4 (rhesus macaque) | 8982 |
| Immune Technology | IT-001-014Ep-1mg | Nef (HIV-1/Clade B) 1mg | 22482 |
| Immune Technology | IT-002-001p-0.1mg | S (1-1190)(Beijing02) | 8982 |
| Immune Technology | IT-001-015Ep-1mg | Nef (HIV-1/Clade C) 1mg | 26160.12 |
| Immune Technology | IT-001-016Ep-1mg | p24 (HIV-1/Clade A) 1mg | 26160.12 |
| Immune Technology | IT-002-010p-0.1mg | Spike Protein (MERS-CoV/EMC 2C/2012) | 8982 |
| Immune Technology | IT-001-017Ep-1mg | p24 (HIV-1/Clade B)(HXBc2) 1mg | 22482 |
| Immune Technology | IT-002-051Ep-0.1mg | SARS Core (1-49 a.a.) | 6282 |
| Immune Technology | IT-002-052Ep-0.1mg | SARS Core (340-390 a.a.) | 6282 |
| Immune Technology | IT-001-017p-1mg | p24 (HXBc2) 1mg | 57402 |
| Immune Technology | IT-001-018Ep-1mg | p27 (SIV/mac239) 1mg | 26160.12 |
| Immune Technology | IT-001-018p-1mg | p27(SIV/mac239) 1mg | 66368.16 |
| Immune Technology | IT-002-054Ep-0.1mg | SARS Matrix | 7309.8 |
| Immune Technology | IT-001-019Ep-1mg | p24 (HIV-1/Clade C) 1mg | 26160.12 |
| Immune Technology | IT-001-020Ep-1mg | p24(HIV-1/Clade B/C(CN54)) 1mg | 22482 |
| Immune Technology | IT-003-00101∆TMp-0.1mg | HA(∆TM)(A/Hawaii/19/2007(H1N1)) | 10451.52 |
| Immune Technology | IT-003-00102∆TMp-0.1mg | HA(∆TM)(H1N1)(A/Fort Monmouth/1/1947) | 10451.52 |
| Immune Technology | IT-003-00103∆TMp-0.1mg | HA(∆TM)(A/Christchurch/16/2010)(H1N1) | 8982 |
| Immune Technology | IT-003-00103p-0.1mg | HA1(A/Christchurch/16/2010)(H1N1) | 10451.52 |
| Immune Technology | IT-001-020p-1mg | p24(HIV-1/Clade B/C(CN54)) 1mg | 57402 |
| Immune Technology | IT-001-021p-1mg | p24 Capsid Protein (HIV-1/Clade A)(Q23-CxC) 1mg | 66792.96 |
| Immune Technology | IT-003-00104ΔTMp-0.1mg | HA(ΔTMp)(H1N1)(A/WSN/1933) | 8982 |
| Immune Technology | IT-003-00105∆TMp-0.1mg | HA(∆TMp)(H1N1)(A/Michigan/45/2015) | 8982 |
| Immune Technology | IT-003-00105p-0.1mg | HA1(H1N1)(A/Michigan/45/2015) | 10451.52 |
| Immune Technology | IT-001-022p-1mg | gp120(SIV/mac239) 1mg | 66792.96 |
| Immune Technology | IT-003-00106∆TMp-0.1mg | HA(ΔTM)(A/California/04/2009)(H1N1) | 10451.52 |
| Immune Technology | IT-003-00107∆TMp-0.05mg | HA(ΔTM)(A/Slovenia/2903/2015)(H1N1) | 9404.28 |
| Immune Technology | IT-003-00108∆TMp-0.1mg | HA(ΔTM)(A/Bolivia/559/2013)(H1N1) | 8982 |
| Immune Technology | IT-003-00108p-0.1mg | HA1(A/Bolivia/559/2013)(H1N1) | 8982 |
| Immune Technology | IT-001-024Ep-1mg | Gag (SIV-1/mac239) 1mg | 22482 |
| Immune Technology | IT-003-0010ΔTMp-0.1mg | HA(∆TM)(H1N1)(A/Puerto Rico/8/1934) | 8982 |
| Immune Technology | IT-003-0010p-0.1mg | HA1 (H1N1/PR8/34) | 8982 |
| Immune Technology | IT-001-025Ep-1mg | Pol (SIV-1/mac239) 1mg | 26160.12 |
| Immune Technology | IT-003-00111p-0.1mg | HA1(A/Ohio/28/2016)(H3N2v) | 8982 |
| Immune Technology | IT-003-00112p-0.1mg | HA1 (A/Iowa/32/2016)(H1N2) | 8982 |
| Immune Technology | IT-003-00113p-0.1mg | HA1 (A/Netherlands/3315/2016)(H1N1) | 8982 |
| Immune Technology | IT-003-00114p-0.1mg | HA1 (A/Hunan/42443/2015)(H1N1) | 8982 |
| Immune Technology | IT-001-026Ep-1mg | Nef (SIV-1/mac239) 1mg | 22482 |
| Immune Technology | IT-003-0011ΔTMp-0.1mg | HA(ΔTM)(H1N1/A/Solomon Islands/3/2006) | 10451.52 |
| Immune Technology | IT-003-0011p-0.1mg | HA1 (H1N1)(A/Solomon Islands/3/2006) | 8982 |
| Immune Technology | IT-001-027Ep-1mg | Nef (SIV-1/mac251) 1mg | 22482 |
| Immune Technology | IT-003-0012Hp-0.1mg | HA(Head Region)(A/Brisbane/59/2007) | 10451.52 |
| Immune Technology | IT-003-0012ΔTMp-0.1mg | HA(ΔTM)(H1N1) (A/Brisbane/59/2007) | 8982 |
| Immune Technology | IT-003-0012p-0.1mg | HA1(H1N1)(A/Brisbane/59/2007) | 10451.52 |
| Immune Technology | IT-003-0013p-0.1mg | HA1(H1N1)(A/WS/33) | 8982 |
| Immune Technology | IT-001-101p-1mg | gp120(MG505.W0M.ENV.A2)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-001-102p-1mg | gp120(MG505.W0M.ENV.H3)(Clade A) 1mg | 57402 |
| Immune Technology | IT-003-0014ΔTMp-0.1mg | HA(ΔTM)(A/South Carolina/1/18/(H1N1)) | 8982 |
| Immune Technology | IT-003-0014p-0.1mg | HA1(A/South Carolina/1/18(H1N1)) | 10451.52 |
| Immune Technology | IT-001-103p-1mg | gp120(MF535.W0M.ENV.D11)(Clade A) 1mg | 57402 |
| Immune Technology | IT-001-105p-1mg | gp120(MI206.W0M.ENV.B1)(Clade A) 1mg | 66368.16 |
| Immune Technology | IT-003-0015p-0.1mg | HA1(A/Bel/1942(H1N1)) | 10451.52 |
| Immune Technology | IT-003-0016p-0.1mg | HA1(A/USSR/92/77(H1N1)) | 10451.52 |
| Immune Technology | IT-001-106p-1mg | gp120(MI206.W0M.ENV.D1)(Clade A) 1mg | 66368.16 |
| Immune Technology | IT-001-107p-1mg | gp120(MJ412.W0M.ENV.B1)(Clade A) 1mg | 66368.16 |
| Immune Technology | IT-003-0017p-0.1mg | HA1(A/Albany/12/1951(H1N1)) | 8982 |
| Immune Technology | IT-003-0018p-0.1mg | HA1(A/Phila/1935(H1N1)) | 8982 |
| Immune Technology | IT-001-108p-1mg | gp120(MJ412.W0M.ENV.C1)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-001-109p-1mg | gp120(MJ613.W0M.ENV.A2)(Clade A) 1mg | 66368.16 |
| Immune Technology | IT-003-0019p-0.1mg | HA1(A/Memphis/1/1987(H1N1)) | 10451.52 |
| Immune Technology | IT-003-001ΔTMp-0.1mg | HA(ΔTM)(H1N1/A/New Caledonia/20/99) | 8982 |
| Immune Technology | IT-001-110p-1mg | gp120(MJ613.W0M.ENV.B1)(Clade A) 1mg | 57402 |
| Immune Technology | IT-003-001p-0.1mg | HA1(H1N1)(A/New Caledonia/20/99) | 8982 |
| Immune Technology | IT-001-111p-1mg | gp120(MK184.W0M,ENV.E4)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-003-001SW1p-0.1mg | HA1(H1N1)(A/swine/Belgium/1/1998) | 8982 |
| Immune Technology | IT-001-112p-1mg | gp120(MK184.W0M,ENV.G3)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-001-113p-1mg | gp120(ML035.W0M.ENV.G2)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-003-001SW2p-0.1mg | HA1(H1N2)(A/swine/Gent/7625/1999) | 8982 |
| Immune Technology | IT-003-0031p-0.1mg | HA(ΔTM)(H2N2)(A/Canada/720/05) | 10451.52 |
| Immune Technology | IT-003-0032ΔTMp-0.1mg | HA(ΔTM)(A/Japan/305/1957(H2N2)) | 8982 |
| Immune Technology | IT-003-003p-0.1mg | HA1 (H2N2)(A/Canada/720/05) | 8982 |
| Immune Technology | IT-001-114p-1mg | gp120(ML035.W0M.ENV.I2)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-001-115p-1mg | gp120(BL035.W6M.ENV.C1)(Clade A) 1mg | 57402 |
| Immune Technology | IT-003-00410∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Johannesburg/33/94) | 8982 |
| Immune Technology | IT-003-00410p-0.1mg | HA1(H3N2)(A/Johannesburg/33/94) | 10451.52 |
| Immune Technology | IT-001-116p-1mg | gp120(ML274.W0M.ENV.B1)(Clade A) 1mg | 57402 |
| Immune Technology | IT-001-117p-1mg | gp120(ML274.W0M.ENV.F1)(Clade A) 1mg | 57402 |
| Immune Technology | IT-001-118p-1mg | gp120(BL274.W6M.ENV.A3)(Clade A) 1mg | 66792.96 |
| Immune Technology | IT-001-119p-1mg | gp120(p1012.TC21.3257)(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-003-00411∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Beijing/32/92) | 8982 |
| Immune Technology | IT-003-00411p-0.1mg | HA1(H3N2)(A/Beijing/32/92) | 8982 |
| Immune Technology | IT-001-120p-1mg | gp120(p1006_11.C3.1601)(Clade B) 1mg | 66368.16 |
| Immune Technology | IT-001-121p-1mg | gp120(p1054.TC4.1499)(Clade B) 1mg | 57402 |
| Immune Technology | IT-003-00412∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Guizhou/54/89) | 8982 |
| Immune Technology | IT-003-00412p-0.1mg | HA1(H3N2)(A/Guizhou/54/89) | 8982 |
| Immune Technology | IT-001-122p-1mg | gp120(p1056.TA11.1826)(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-001-123p-1mg | gp120(p1058_11.B11.1550)(Clade B) 1mg | 57402 |
| Immune Technology | IT-003-00414∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Christchurch/4/85) | 8982 |
| Immune Technology | IT-003-00414p-0.1mg | HA1(H3N2)(A/Christchurch/4/85) | 10451.52 |
| Immune Technology | IT-001-124p-1mg | gp120(p1059_09.A4.1460)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-125p-1mg | gp120(p62357_14.D3.4589)(Clade B) 1mg | 57402 |
| Immune Technology | IT-003-00415∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Mississippi/1/85) | 8982 |
| Immune Technology | IT-003-00415p-0.1mg | HA1(H3N2)(A/Mississippi/1/85) | 8982 |
| Immune Technology | IT-001-126p-1mg | gp120(p6240_08.TA5.4622)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-127p-1mg | gp120(p6244_13.B5.4576)(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-003-00416∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Philippines/2/82) | 8982 |
| Immune Technology | IT-003-00416p-0.1mg | HA1(H3N2)(A/Philippines/2/82) | 8982 |
| Immune Technology | IT-001-128p-1mg | gp120(p63358.p3.4013)(Clade B) 1mg | 66368.16 |
| Immune Technology | IT-001-129p-1mg | gp120(p700010040.C9.4520)(Clade B) 1mg | 57402 |
| Immune Technology | IT-003-00417∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Victoria/3/75) | 8982 |
| Immune Technology | IT-003-00417p-0.1mg | HA1(H3N2)(A/Victoria/3/75) | 10451.52 |
| Immune Technology | IT-001-130p-1mg | gp120(p700010058.A4.4357)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-131p-1mg | gp120(p9014_01.TB1.4769)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-132p-1mg | gp120(p9021_14.B2.4571)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-133p-1mg | gp120(pPRB926_04.A9.4239)(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-001-134p-1mg | gp120(pPRB931_06.TC3.4930)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-135p-1mg | gp120(pSC05.8C11.2344)(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-003-00418∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Hong Kong/8/68) | 10451.52 |
| Immune Technology | IT-003-00419∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Texas/1/77) | 8982 |
| Immune Technology | IT-001-136p-1mg | gp120(pSC45.4B5.2631)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-137p-1mg | gp120(pWEAUd15.410.5017)(Clade B) 1mg | 66792.96 |
| Immune Technology | IT-003-00419p-0.1mg | HA1(H3N2)(A/Texas/1/77) | 8982 |
| Immune Technology | IT-003-0041ΔTMp-0.05mg | HA(ΔTM)(H3N2/Wisconsin/67/X-161/2005) | 8082 |
| Immune Technology | IT-001-138∆TMp-1mg | gp140(HIV-1/LAI)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-138p-1mg | gp120(LAI)(Clade B) 1mg | 57402 |
| Immune Technology | IT-003-0041p-0.1mg | HA(ΔTM)(H3N2/Wisconsin/67/X-161/2005) | 8982 |
| Immune Technology | IT-001-139p-1mg | gp120(Du151)(Clade C) 1mg | 66792.96 |
| Immune Technology | IT-003-00420∆TMp-0.1mg | H3(∆TM)(H3N2)(A/England/42/72) | 10451.52 |
| Immune Technology | IT-001-140p-1mg | gp140(mac239)(SIV) 1mg | 57402 |
| Immune Technology | IT-003-00420p-0.1mg | HA1(H3N2)(A/England/42/72) | 8982 |
| Immune Technology | IT-003-00421∆TMp-0.1mg | HA(∆TM)(H3N2)(A/VICTORIA/208/2009) | 8982 |
| Immune Technology | IT-001-141p-1mg | gp140(SIVsmE660) 1mg | 66792.96 |
| Immune Technology | IT-003-00421p-0.1mg | HA1(H3N2)(A/VICTORIA/210/2009) | 8982 |
| Immune Technology | IT-001-142p-1mg | gp120(SIVsmE660) 1mg | 57402 |
| Immune Technology | IT-001-145p-0.5mg | gp140(SHIV SF162P3)(HIV-1) 0.5mg | 51138 |
| Immune Technology | IT-001-146p-1mg | gp120(SHIV SF162P3)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-003-00422p-0.1mg | HA1(A/Kentucky/05/2011)(H3N2) | 10451.52 |
| Immune Technology | IT-003-00423∆TMp-0.1mg | HA(∆TM)(A/Victoria/361/2011) (H3N2) | 10451.52 |
| Immune Technology | IT-003-00423p-0.1mg | HA1(A/Victoria/361/2011)(H3N2) | 8982 |
| Immune Technology | IT-001-147p-1mg | gp120(smE543)(SIV) 1mg | 57402 |
| Immune Technology | IT-001-148p-0.5mg | gp140(smE543)(SIV) 0.5mg | 59504.22 |
| Immune Technology | IT-003-00424p-0.1mg | HA1(A/Chiang Rai/277/2011)(H3N2) | 8982 |
| Immune Technology | IT-003-00425p-0.1mg | HA1(A/Brisbane/299/2011 )(H3N2) | 8982 |
| Immune Technology | IT-003-00426p-0.1mg | HA1(A/Hawaii/22/2012)(H3N2) | 10451.52 |
| Immune Technology | IT-003-00427p-0.1mg | HA1(A/Texas/50/2012)(H3N2) | 8982 |
| Immune Technology | IT-001-149p-1mg | gp120(00KE_KER2018)(HIV-1/Clade A) 1mg | 57402 |
| Immune Technology | IT-001-150p-1mg | gp120(CM235/CRF01_AE)(HIV-1) 1mg | 66792.96 |
| Immune Technology | IT-003-00428p-0.1mg | HA1(A/Switzerland/9715293/2013)(H3N2) | 8982 |
| Immune Technology | IT-003-00428ΔTMp-0.1mg | HA(ΔTM)(H3N2)(A/Switzerland/9715293/2013) | 8982 |
| Immune Technology | IT-003-00429p-0.1mg | HA1(H3N2)(A/California/7/2004) | 8982 |
| Immune Technology | IT-003-0042ΔTMp-0.1mg | HA(ΔTM)(H3N2)(A/Brisbane/10/2007) | 8982 |
| Immune Technology | IT-003-0042p-0.1mg | HA1(H3N2)(A/Brisbane/10/2007) | 8982 |
| Immune Technology | IT-003-00430ΔTMp-0.05mg | HA(A/Hong Kong/4801/2014)(H3N2) | 11498.76 |
| Immune Technology | IT-001-151p-1mg | gp120(HIV-1/Clade 01_AE/CM240) 1mg | 66792.96 |
| Immune Technology | IT-001-152p-1mg | gp120(HIV-1/Clade 01_AE/90TH_CM244) 1mg | 57402 |
| Immune Technology | IT-003-00430p-0.1mg | HA1(A/Hong Kong/4801/2014)(H3N2) | 10451.52 |
| Immune Technology | IT-003-00431p-0.1mg | HA1(A/Beijing/353/1989)(H3N2) | 8982 |
| Immune Technology | IT-003-00432p-0.1mg | HA1(A/Bangkok/1/1979)(H3N2) | 10451.52 |
| Immune Technology | IT-003-00433ΔTMp-0.05mg | HA(ΔTM)(A/NEW CALEDONIA/71/2014)(H3N2) | 11425.5 |
| Immune Technology | IT-003-00434p-0.1mg | HA1(A/Singapore/INFIMH-16-0019/2016)(H3N2) | 10451.52 |
| Immune Technology | IT-001-153p-1mg | gp120(HIV-1/Clade CRF02_AG/98US_MSC5007) 1mg | 57402 |
| Immune Technology | IT-001-154p-1mg | gp120(HIV-1/Clade CRF02_AG/ 01CM_0002BBY 1mg | 66792.96 |
| Immune Technology | IT-001-155p-1mg | gp120(HIV-1/Clade CRF02_AG/01CM_1475MV) 1mg | 57402 |
| Immune Technology | IT-001-156FRp-1mg | gp120(SIV/mac251)(Mucosal Funder Strain 216.94.A2) 1mg | 66368.16 |
| Immune Technology | IT-003-0043ΔTMp-0.1mg | HA(ΔTM)(A/Aichi/2/1968(H3N2)) | 8982 |
| Immune Technology | IT-003-0043p-0.1mg | HA1(A/Aichi/2/1968(H3N2)) | 8982 |
| Immune Technology | IT-003-0044ΔTMp-0.1mg | HA(∆TM)(H3N2/Wisconsin/15/2009) | 10451.52 |
| Immune Technology | IT-003-0045ΔTMp-0.1mg | HA(∆TM)(H3N2/Perth/16/2009) | 8982 |
| Immune Technology | IT-003-0045p-0.1mg | HA1(H3N2/Perth/16/2009) | 10384.92 |
| Immune Technology | IT-003-0046∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Fujian/411/02) | 10451.52 |
| Immune Technology | IT-001-156FVp-1mg | gp120(SIV/mac251)(Mucosal Funder Strain SIVmac251v31523ru28) 1mg | 57402 |
| Immune Technology | IT-003-0046p-0.1mg | HA1(H3N2)(A/Fujian/411/02) | 8982 |
| Immune Technology | IT-003-0047ΔTMp-0.1mg | H3(∆TM)(H3N2)(A/Panama/07/99) | 8982 |
| Immune Technology | IT-003-0047p-0.1mg | HA1(H3N2)(A/Panama/07/99) | 8982 |
| Immune Technology | IT-003-0048∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Sydney/5/97) | 8982 |
| Immune Technology | IT-001-156p-1mg | gp120(mac251)(SIV) 1mg | 66792.96 |
| Immune Technology | IT-003-0048p-0.1mg | HA1(H3N2)(A/Sydney/5/97) | 8982 |
| Immune Technology | IT-003-0049∆TMp-0.1mg | H3(∆TM)(H3N2)(A/Wuhan/359/95) | 10451.52 |
| Immune Technology | IT-001-157p-1mg | gp120(SIVcpz EK505) 1mg | 66792.96 |
| Immune Technology | IT-003-0049p-0.1mg | HA1(H3N2)(A/Wuhan/359/95) | 8982 |
| Immune Technology | IT-003-004ΔTMp-0.1mg | HA(∆TM) (H3N2)(Wyoming/3/03) | 8982 |
| Immune Technology | IT-001-158p-1mg | gp120(SIVcpz MB66) 1mg | 57402 |
| Immune Technology | IT-003-004p-0.1mg | HA1 (H3N2)(A/Wyoming/3/03) | 8982 |
| Immune Technology | IT-003-004SW1p-0.1mg | HA1(A/Iowa/08/2011(H3N2)) | 10451.52 |
| Immune Technology | IT-001-160p-1mg | gp120(HIV-1/Clade B/C(CN54)) 1mg | 57402 |
| Immune Technology | IT-001-161p-1mg | gp140(HIV-1/Clade B/C(CN54)) 1mg | 57402 |
| Immune Technology | IT-003-004SW2p-0.1mg | HA1(A/Minnesota/09/2010(H3N2)) | 8982 |
| Immune Technology | IT-003-004SW3p-0.1mg | HA1(A/Kansas/13/2009(H3N2)) | 10451.52 |
| Immune Technology | IT-003-004SW4p-0.1mg | HA1(A/Pennsylvania/14/2010(H3N2)) | 8982 |
| Immune Technology | IT-003-004SW5p-0.1mg | HA1(A/Ontario/RV1273/2005(H3N2)) | 10451.52 |
| Immune Technology | IT-003-004SW6p-0.1mg | HA1(H3N2v) (A/Indiana/07/2012) | 8982 |
| Immune Technology | IT-003-004SW7p-0.1mg | HA1(H3N2)(A/swine/Flanders/1/1998) | 8982 |
| Immune Technology | IT-001-162p-1mg | gp140(HIV-1/Clade B/C)(Consensus) 1mg | 66792.96 |
| Immune Technology | IT-001-163p-1mg | gp120(HIV-1/Clade B/C)(Consensus) 1mg | 66792.96 |
| Immune Technology | IT-003-00511p-0.1mg | HA (A/Egypt/2321-NAMRU3/2007 (H5N1)) | 8982 |
| Immune Technology | IT-003-00512p-0.1mg | HA (A/Egypt/chicken/2253-1/2006 (H5N1)) | 8982 |
| Immune Technology | IT-003-00513p-0.1mg | HA (A/goose/Guiyang/337/2006 (H5N1)) | 10451.52 |
| Immune Technology | IT-003-00514p-0.1mg | HA (A/Japanese white-eye/Hong Kong/1038/2006 (H5N1)) | 8982 |
| Immune Technology | IT-001-164p-1mg | gp120(HIV-1/Clade AE)(A244) 1mg | 66792.96 |
| Immune Technology | IT-001-165p-1mg | gp140(HIV-1/Clade AE)(A244) 1mg | 57402 |
| Immune Technology | IT-003-00515p-0.1mg | HA (A/Common magpie/Hong Kong/5052/2007(H5N1)) | 8982 |
| Immune Technology | IT-003-00516p-0.1mg | HA (A/chicken/India/NIV33487/2006 (H5N1)) | 10451.52 |
| Immune Technology | IT-003-00517p-0.1mg | HA(∆TM)(A/Egypt/3300-NAMRU3/08(H5N1)) | 10451.52 |
| Immune Technology | IT-003-00518p-0.1mg | HA(∆TM)(A/chicken/Vietnam/NCVD-016/08(H5N1)) | 8982 |
| Immune Technology | IT-003-00519∆TMp-0.1mg | HA(∆TM)(H5N1)(A/Hubei/1/2010) | 8982 |
| Immune Technology | IT-001-166p-1mg | gp120(CH181)(CRF07_BC) 1mg | 57402 |
| Immune Technology | IT-001-167p-1mg | gp140(HIV-1/Clade AE)(Consensus) 1mg | 66368.16 |
| Immune Technology | IT-003-00519p-0.1mg | HA1(H5N1)(A/Hubei/1/2010) | 8982 |
| Immune Technology | IT-001-168p-1mg | gp120(HIV-1/Clade AE)(Consensus) 1mg | 57402 |
| Immune Technology | IT-003-0051p-0.1mg | H5(H5N1)(A/Vietnam/1203/2004) | 8982 |
| Immune Technology | IT-003-00520∆TMp-0.1mg | HA(∆TM)(H5N1)(A/Egypt/N03072/2010) | 10451.52 |
| Immune Technology | IT-003-00520p-0.1mg | HA1(H5N1)(A/Egypt/N03072/2010) | 10451.52 |
| Immune Technology | IT-003-00521p-0.1mg | HA1 (A/chicken/Egypt/S3280D/2011)(H5N1) | 10451.52 |
| Immune Technology | IT-001-169p-1mg | gp140(TV-1)(HIV-1/Clade C) 1mg | 66792.96 |
| Immune Technology | IT-003-00522p-0.1mg | HA1(A/Indonesia/NIHRD11771/2011)(H5N1) | 8982 |
| Immune Technology | IT-003-00523p-0.1mg | HA1 (A/chicken/Vietnam/NCVD-700/2011)(H5N1) | 8982 |
| Immune Technology | IT-001-170p-1mg | gp120(TV1)(HIV-1/Clade C) 1mg | 66792.96 |
| Immune Technology | IT-003-00524p-0.1mg | HA1(A/Cambodia/V0401301/2011)(H5N1)) | 10451.52 |
| Immune Technology | IT-003-00525p-0.1mg | HA1(A/chicken/Bangladesh/11rs1984-30/2011)(H5N1) | 8982 |
| Immune Technology | IT-003-00526p-0.1mg | HA1(A/Cambodia/R0405050/2007 (H5N1)) | 10384.92 |
| Immune Technology | IT-003-00527ΔTMp-0.1mg | HA(ΔTM)(H5N1)(A/chicken/Viet Nam/NCVD-03/2008) | 8982 |
| Immune Technology | IT-003-00527p-0.1mg | HA1(H5N1)(A/chicken/Viet Nam/NCVD-03/2008) | 8982 |
| Immune Technology | IT-001-171p-1mg | gp140(BL10)(HIV-1/Clade B) 1mg | 57402 |
| Immune Technology | IT-001-172p-1mg | gp120(BL10)(HIV-1/Clade B) 1mg | 57402 |
| Immune Technology | IT-003-00528p-0.1mg | HA1(A/turkey/Germany-MV/R2472/2014)(H5N8) | 8982 |
| Immune Technology | IT-003-0052ΔTMp-0.1mg | HA(ΔTM)(A/Indonesia/5/2005(H5N1)) | 10451.52 |
| Immune Technology | IT-001-174p-1mg | gp120 (001428-2.4)(Clade C) 1mg | 57402 |
| Immune Technology | IT-003-0052p-0.1mg | H5 (H5N1)(A/Indonesia/5/2005) | 8982 |
| Immune Technology | IT-003-00530p-0.1mg | HA1(A/environment/Hubei/950/2013)(H5N1) | 8982 |
| Immune Technology | IT-001-175p-1mg | gp120(Q461.d1)(Clade A) 1mg | 57402 |
| Immune Technology | IT-001-176p-1mg | gp120(BG505.W6M.ENV.C1)(Clade A) 1mg | 66368.16 |
| Immune Technology | IT-003-00531p-0.1mg | HA1(A/northern pintail/Washington/40964/2014)(H5N2) | 10451.52 |
| Immune Technology | IT-003-00532p-0.1mg | HA1(A/turkey/BC/FAV10/2014)(H5N2) | 10451.52 |
| Immune Technology | IT-001-177p-1mg | gp120(BG505.W6M.ENV.C1.A204E) (Clade A) 1mg | 66368.16 |
| Immune Technology | IT-001-178p-1mg | gp120(QA255.21P.ENV.A17)(Clade A) 1mg | 57402 |
| Immune Technology | IT-003-00533p-0.1mg | HA1(A/Sichuan/26221/2014)(H5N6) | 8982 |
| Immune Technology | IT-001-179p-1mg | gp120 (BF520.M6P.D1)(Clade A) 1mg | 57402 |
| Immune Technology | IT-001-191p-1mg | gp120 (C2-94UG114)(HIV-1/Clade D) 1mg | 57402 |
| Immune Technology | IT-003-00534p-0.1mg | HA1(A/Guizhou/1/2013)(H5N1) | 10451.52 |
| Immune Technology | IT-003-00535p-0.1mg | HA1(A/chicken/Iowa/04-20/2015) (H5N2) | 10451.52 |
| Immune Technology | IT-001-201p-1mg | gp120(HIV-2/Ben) 1mg | 57402 |
| Immune Technology | IT-003-00536p-0.1mg | HA1(A/tufted duck/Germany-SH/R8444/2016) (H5N8) | 10451.52 |
| Immune Technology | IT-001-202p-1mg | gp120(HIV-2/NIH-Z) 1mg | 57402 |
| Immune Technology | IT-003-00537ΔTMp-0.1mg | HA(ΔTM)(A/common magpie/Hong Kong/5052/2007)(H5N1) | 10451.52 |
| Immune Technology | IT-003-00538p-0.1mg | HA1 (A/Hubei/29578/2016)(H5N6) | 10451.52 |
| Immune Technology | IT-003-00539p-0.1mg | HA1 (A/duck/Hyogo/1/2016)(H5N6) | 8982 |
| Immune Technology | IT-001-203p-1mg | gp120(HIV-2/B_UC1) 1mg | 57402 |
| Immune Technology | IT-003-0053ΔTMp-0.1mg | HA(ΔTM)(A/Anhui/1/2005(H5N1)) | 8982 |
| Immune Technology | IT-003-0053p-0.1mg | H5 (H5N1)(A/Anhui/1/2005) | 8982 |
| Immune Technology | IT-003-00540p-0.1mg | HA1 (A/chicken/Ghana/20/2015(H5N1)) | 10451.52 |
| Immune Technology | IT-003-0054p-0.1mg | HA (B/Malaysia/2506/2004) | 8982 |
| Immune Technology | IT-003-0055p-0.1mg | HA (A/Bar-headed Goose/Qinghai/12/05) | 10451.52 |
| Immune Technology | IT-003-0056p-0.1mg | HA1(H5N1)(A/Hong Kong/156/97) | 8982 |
| Immune Technology | IT-001-211p-0.5mg | gp70(MLV)-V1V2(HIV-1/CN54) 0.5mg | 58230 |
| Immune Technology | IT-001-212p-1mg | gp70(MLV)-V1V2(HIV-1/AE/A244) 1mg | 57402 |
| Immune Technology | IT-003-0057p-0.1mg | HA1(H5N1)(A/Hong Kong/483/97) | 8982 |
| Immune Technology | IT-003-0058p-0.1mg | HA2(A/Vietnam/1203/2004)(H5N1) | 8982 |
| Immune Technology | IT-003-0059p-0.1mg | HA1(H5N1)(A/Hong Kong/213/2003) | 10384.92 |
| Immune Technology | IT-003-005p-0.1mg | HA1(H5N1)(A/Vietnam/1194/2004) | 10451.52 |
| Immune Technology | IT-003-0061ΔTMp-0.1mg | HA(ΔTM)(A/Swine/99(H4N6)) | 8982 |
| Immune Technology | IT-003-0066p-0.1mg | HA1(H6N2)(A/chicken/Guangdong/C273/2011) | 8982 |
| Immune Technology | IT-001-214p-0.5mg | gp70(MLV)-V1V2(HIV-1/Clade B/Case A2) 0.5mg | 59504.22 |
| Immune Technology | IT-001-317p-1mg | hCD317(ΔTMs) 1mg | 66792.96 |
| Immune Technology | IT-003-0067p-0.1mg | HA1(H6N6)(A/duck/Eastern China/11/2009) | 8982 |
| Immune Technology | IT-003-006ΔTMp-0.1mg | HA(ΔTM)(H4N6)(A/Swine/Ontario/01911-1/99) | 10451.52 |
| Immune Technology | IT-003-006p-0.1mg | HA1(H4N6)(Influenza A) | 10451.52 |
| Immune Technology | IT-001-CD4d1d2p-1mg | Human CD4(D1D2 region) 1mg | 66792.96 |
| Immune Technology | IT-003-0071ΔTMp-0.1mg | HA(ΔTM)(A/chicken/Jalisco/CPA1/2012(H7N3)) | 10451.52 |
| Immune Technology | IT-003-0071p-0.1mg | HA1 (A/chicken/Jalisco/CPA1/2012(H7N3)) | 8982 |
| Immune Technology | IT-001-CONA1p-1mg | gp120(Con_A1) 1mg | 57402 |
| Immune Technology | IT-001-CONA2p-1mg | gp120(Con_A2) 1mg | 57402 |
| Immune Technology | IT-003-0072ΔTMp-0.1mg | HA(ΔTM)(A/environment/California/7451/2010(H7N3)) | 8982 |
| Immune Technology | IT-001-CONBp-1mg | gp120(Con_B) 1mg | 57402 |
| Immune Technology | IT-001-CONCp-1mg | gp120(Con_C)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-003-0072p-0.1mg | HA1 (A/environment/California/7451/2010(H7N3)) | 10451.52 |
| Immune Technology | IT-003-0073ΔTMp-0.1mg | HA(ΔTM)(H7N9)(A/Shanghai/1/2013) | 10384.92 |
| Immune Technology | IT-001-CONp-1mg | gp120(Con of Cons) 1mg | 57402 |
| Immune Technology | IT-003-0073p-0.1mg | HA1(H7N9)(A/Shanghai/1/2013) | 8982 |
| Immune Technology | IT-003-0074ΔTMp-0.1mg | HA(ΔTM)(H7N9)(A/Shanghai/2/2013) | 8982 |
| Immune Technology | IT-001-RB10p-1mg | gp120(pTHRO4156)(Clade B) 1mg | 57402 |
| Immune Technology | IT-003-0074p-0.1mg | HA1(H7N9)(A/Shanghai/2/2013) | 8982 |
| Immune Technology | IT-003-0075p-0.1mg | HA1(A/Guangdong/17SF003/2016)(H7N9) | 8982 |
| Immune Technology | IT-001-RB11p-1mg | gp120(pCAAN5342) 1mg | 57402 |
| Immune Technology | IT-001-RB12p-1mg | gp120(SC422661.8)(CladeB) 1mg | 57402 |
| Immune Technology | IT-003-0076p-0.1mg | HA1(A/Hong Kong/125/2017(H7N9) | 8982 |
| Immune Technology | IT-003-007ΔTMp-0.1mg | HA(ΔTM)(H7N7/England/268/96) | 10451.52 |
| Immune Technology | IT-001-RB1p-1mg | gp120(6535)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-003-0081∆TMp-0.1mg | HA(∆TM)(A/Netherlands/219/03(H7N7)) | 8982 |
| Immune Technology | IT-001-RB2p-1mg | gp120(QH0692) 1mg | 57402 |
| Immune Technology | IT-003-008ΔTMp-0.1mg | HA(ΔTM)(H7N7)(A/chicken/Netherlands/1/03) | 10451.52 |
| Immune Technology | IT-003-008p-0.1mg | HA1 (H7N7)(A/chicken/Netherlands/1/03) | 8982 |
| Immune Technology | IT-001-RB3p-1mg | gp120(PVO) 1mg | 57402 |
| Immune Technology | IT-003-00910p-0.1mg | HA1(A/Hong Kong/308/2014)(H9N2) | 10451.52 |
| Immune Technology | IT-003-0091ΔTMp-0.1mg | HA(ΔTM)(A/Hongkong/1073/1999(H9N2)) | 8982 |
| Immune Technology | IT-001-RB4p-1mg | gp120(TRO)(Clade B) 1mg | 57402 |
| Immune Technology | IT-001-RB5p-1mg | gp120(AC10.0)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-003-0091p-0.1mg | HA1(A/Hong Kong/1073/99)(H9N2) | 8982 |
| Immune Technology | IT-003-0092ΔTMp-0.1mg | HA(ΔTM)(A/Chicken/Hong Kong/G9/97(H9N2)) | 8982 |
| Immune Technology | IT-003-0093∆TMp-0.1mg | HA(∆TM)(A/Hong Kong/2108/03(H9N2)) | 8982 |
| Immune Technology | IT-003-0094∆TMp-0.1mg | HA(∆TM)(H9N2)(A/Hong Kong/33982/2009) | 10451.52 |
| Immune Technology | IT-003-0094p-0.1mg | HA1(H9N2)(A/Hong Kong/33982/2009) | 8982 |
| Immune Technology | IT-003-0095p-0.1mg | HA1(A/chicken/India/IVRI-0011/2011)(H9N2) | 8982 |
| Immune Technology | IT-001-RB6p-1mg | gp120(pWITO4160) 1mg | 57402 |
| Immune Technology | IT-001-RB7p-1mg | gp120(pTRJO4551)(Clade B) 1mg | 57402 |
| Immune Technology | IT-003-0096p-0.1mg | HA1(A/spot-billed duck/Jiangxi/33 /2011)(H9N2) | 8982 |
| Immune Technology | IT-003-0097p-0.1mg | HA1(A/swine/Shanghai/Y1/2009)(H9N2) | 10451.52 |
| Immune Technology | IT-001-RB8p-1mg | gp120(pREJO4541) 1mg | 57402 |
| Immune Technology | IT-001-RB9p-1mg | gp120(pRHPA4259) 1mg | 66792.96 |
| Immune Technology | IT-003-0099p-0.1mg | HA1(A/chicken/Wenzhou/688b/2013)(H9N2) | 8982 |
| Immune Technology | IT-001-RC10p-1mg | gp120(ZM135M.PL10a)(HIV-1) 1mg | 57402 |
| Immune Technology | IT-001-RC11p-1mg | gp120(CAP45.2.00) 1mg | 57402 |
| Immune Technology | IT-003-009ΔTMp-0.1mg | HA(ΔTM)(H9N2/Guinea fowl/Hong Kong/WF10/99) | 10451.52 |
| Immune Technology | IT-003-009p-0.1mg | HA1 (H9N2)(A/Guinea fowl/Hong Kong/WF10) | 10451.52 |
| Immune Technology | IT-001-RC12p-1mg | gp120(CAP210.2.00)(Clade C) 1mg | 66792.96 |
| Immune Technology | IT-003-010p-0.1mg | HA1(H8N4)(Influenza A) | 8982 |
| Immune Technology | IT-003-0111p-0.1mg | HA1(A/duck/Guangdong/E1/2012)(H10N8) | 8982 |
| Immune Technology | IT-001-RC1p-1mg | gp120(Du156.12)(Clade C) 1mg | 57402 |
| Immune Technology | IT-003-011∆TMp-0.1mg | H10(∆TM)(H10N7) | 8982 |
| Immune Technology | IT-001-RC2p-1mg | gp120(Du172.17)(Clade C) 1mg | 66792.96 |
| Immune Technology | IT-003-011p-0.1mg | HA1(A/blue-winged teal/Louisiana/Sg-00073/07(H10N7)) | 10451.52 |
| Immune Technology | IT-001-RC3p-1mg | gp120(Du422.1)(Clade C) 1mg | 66792.96 |
| Immune Technology | IT-001-RC4p-1mg | gp120(ZM197M.PB7) (Clade C) 1mg | 66792.96 |
| Immune Technology | IT-003-012∆TMp-0.1mg | H11(∆TM)(H11N2) | 8982 |
| Immune Technology | IT-001-RC5p-1mg | gp120(ZM214M.PL15) (Clade C) 1mg | 57402 |
| Immune Technology | IT-001-RC6p-1mg | gp120(ZM233M.PB6) (Clade C) 1mg | 66792.96 |
| Immune Technology | IT-001-RC7p-1mg | gp120(ZM249M.PL1)(Clade C) 1mg | 66792.96 |
| Immune Technology | IT-001-RC8p-1mg | gp120(ZM53M.PB12)(Clade C) 1mg | 57402 |
| Immune Technology | IT-003-013∆TMp-0.1mg | H12(∆TM)(H12N5) | 10451.52 |
| Immune Technology | IT-001-RC9p-1mg | gp120(ZM109F.PB4) (Clade C) 1mg | 57402 |
| Immune Technology | IT-003-013p-0.1mg | HA1(H12N5)(Influenza A) | 8982 |
| Immune Technology | IT-001-rhCD4-1mg | CD4 (rhesus macaque) 1mg | 57402 |
| Immune Technology | IT-003-014ΔTMp-0.1mg | HA(ΔTM)(H13N8)(A/black-headed gull/Netherlands/1/00) | 8982 |
| Immune Technology | IT-002-001p-1mg | S (1-1190)(Beijing02) 1mg | 57402 |
| Immune Technology | IT-003-014p-0.1mg | HA1(H13N8)(A/black-headed gull/Netherlands/1/00) | 10451.52 |
| Immune Technology | IT-003-015ΔTMp-0.1mg | HA(H14N5)(A/mallard/Astrakhan/263/1982) | 8982 |
| Immune Technology | IT-003-015p-0.1mg | HA1(H14N5)(A/mallard/Astrakhan/263/1982) | 8982 |
| Immune Technology | IT-003-016ΔTMp-0.1mg | HA(ΔTM)(H15N8)(A/duck/AUS/341/1983) | 8982 |
| Immune Technology | IT-003-016p-0.1mg | HA1(H15N8)(A/duck/AUS/341/1983) | 8982 |
| Immune Technology | IT-002-010p-1mg | Spike Protein (MERS-CoV/EMC 2C/2012) 1mg | 57402 |
| Immune Technology | IT-003-017ΔTMp-0.1mg | HA(ΔTM)(H16N3)(A/black-headed gull/Sweden/5/99) | 8982 |
| Immune Technology | IT-003-017p-0.1mg | HA1(H16N3)(A/black-headed gull/Sweden/5/99) | 10451.52 |
| Immune Technology | IT-003-018ΔTMp-0.1mg | HA(ΔTM)(H5N2) | 10451.52 |
| Immune Technology | IT-002-051Ep-0.5mg | SARS Core (1-49 a.a.) 0.5mg | 17082 |
| Immune Technology | IT-002-052Ep-1mg | SARS Core (340-390 a.a.) 1mg | 22482 |
| Immune Technology | IT-003-019ΔTMp-0.1mg | HA(ΔTM)(H5N3) | 8982 |
| Immune Technology | IT-003-020ΔTMp-0.1mg | HA(ΔTM)(H5N8) | 10451.52 |
| Immune Technology | IT-003-0211p-0.1mg | HA1(H6N1)(A/quail/Hong Kong/1721-30/99) | 8982 |
| Immune Technology | IT-003-021ΔTMp-0.1mg | HA(ΔTM)(A/2007(H6N1)) | 10451.52 |
| Immune Technology | IT-003-022∆TMp-0.1mg | H17(ΔTM)(A/little yellow-shoulderedbat /Guatemala/153/2009(H17N10)) | 10451.52 |
| Immune Technology | IT-003-022p-0.1mg | HA1(H17)(A/little yellow-shoulderedbat/ Guatemala/153/2009(H17N10)) | 8982 |
| Immune Technology | IT-002-053Ep-0.5mg | SARS Envelope 0.5mg | 19876.68 |
| Immune Technology | IT-002-054Ep-0.5mg | SARS Matrix 0.5mg | 17082 |
| Immune Technology | IT-003-023p-0.1mg | NP (H5N1)(A/Indonesia/5/2005) | 8982 |
| Immune Technology | IT-003-024Ep-0.1mg | NP(H3N2)(A/Brisbane/10/2007) | 6282 |
| Immune Technology | IT-003-025Ep-0.1mg | M1(A/Thailand/1(KAN-1)/2004(H5N1)) | 6282 |
| Immune Technology | IT-003-00101∆TMp-1mg | HA(∆TM)(A/Hawaii/19/2007(H1N1)) 1mg | 66792.96 |
| Immune Technology | IT-003-00102∆TMp-1mg | HA(∆TM)(H1N1)(A/Fort Monmouth/1/1947) 1mg | 66368.16 |
| Immune Technology | IT-003-026Ep-0.1mg | NP(A/Thailand/1(KAN-1)/2004(H5N1)) | 6282 |
| Immune Technology | IT-003-00103∆TMp-1mg | HA(∆TM)(A/Christchurch/16/2010)(H1N1) 1mg | 66792.96 |
| Immune Technology | IT-003-00103p-1mg | HA1(A/Christchurch/16/2010)(H1N1) 1mg | 57402 |
| Immune Technology | IT-003-00104ΔTMp-1mg | HA(ΔTMp)(H1N1)(A/WSN/1933) 1mg | 66792.96 |
| Immune Technology | IT-003-00105∆TMp-1mg | HA(∆TMp)(H1N1)(A/Michigan/45/2015) 1mg | 57402 |
| Immune Technology | IT-003-00105p-1mg | HA1(H1N1)(A/Michigan/45/2015) 1mg | 57402 |
| Immune Technology | IT-003-028Ep-0.1mg | NP(H1N1)(A/Brisbane/59/2007) | 7309.8 |
| Immune Technology | IT-003-029Ep-0.1mg | NP(A/Netherlands/219/2003(H7N7)) | 6282 |
| Immune Technology | IT-003-00106∆TMp-1mg | HA(ΔTM)(A/California/04/2009)(H1N1) 1mg | 66792.96 |
| Immune Technology | IT-003-030Ep-0.1mg | NP(A/HK/2108/2003(H9N2)) | 6282 |
| Immune Technology | IT-003-00107∆TMp-0.5mg | HA(ΔTM)(A/Slovenia/2903/2015)(H1N1) 0.5mg | 51138 |
| Immune Technology | IT-003-031Ep-0.1mg | NS1(A/Brisbane/10/2007 (H3N2)) | 6282 |
| Immune Technology | IT-003-00108∆TMp-1mg | HA(ΔTM)(A/Bolivia/559/2013)(H1N1) 1mg | 66792.96 |
| Immune Technology | IT-003-032Ep-0.1mg | M1 (A/New Caledonia/20/1999 (H1N1)) | 6282 |
| Immune Technology | IT-003-00108p-1mg | HA1(A/Bolivia/559/2013)(H1N1) 1mg | 57402 |
| Immune Technology | IT-003-0010ΔTMp-1mg | HA(∆TM)(H1N1)(A/Puerto Rico/8/1934) 1mg | 57402 |
| Immune Technology | IT-003-0010p-1mg | HA1 (H1N1/PR8/34) 1mg | 57402 |
| Immune Technology | IT-003-033Ep-0.1mg | M1(H3N2)(A/Wyoming/3/03) | 6282 |
| Immune Technology | IT-003-034Ep-0.1mg | NP (B/Brisbane/60/2008) | 6282 |
| Immune Technology | IT-003-00111p-1mg | HA1(A/Ohio/28/2016)(H3N2v) 1mg | 57402 |
| Immune Technology | IT-003-00112p-1mg | HA1 (A/Iowa/32/2016)(H1N2) 1mg | 66792.96 |
| Immune Technology | IT-003-035Ep-0.1mg | M1 (B/Brisbane/60/2008) | 7309.8 |
| Immune Technology | IT-003-036Ep-0.1mg | M1(A/Victoria/361/2011)(H3N2) | 7309.8 |
| Immune Technology | IT-003-00113p-1mg | HA1 (A/Netherlands/3315/2016)(H1N1) 1mg | 57402 |
| Immune Technology | IT-003-00114p-1mg | HA1 (A/Hunan/42443/2015)(H1N1) 1mg | 57402 |
| Immune Technology | IT-003-036p-0.1mg | NP (A/little yellow-shoulderedbat/Guatemala/153/2009(H17N10)) | 10451.52 |
| Immune Technology | IT-003-0011ΔTMp-1mg | HA(ΔTM)(H1N1/A/Solomon Islands/3/2006) 1mg | 66792.96 |
| Immune Technology | IT-003-0011p-1mg | HA1 (H1N1)(A/Solomon Islands/3/2006) 1mg | 66792.96 |
| Immune Technology | IT-003-037Ep-0.1mg | M1(B/Hubei Wujigang/158/2009) | 6282 |
| Immune Technology | IT-003-0012Hp-1mg | HA(Head Region)(A/Brisbane/59/2007) 1mg | 66792.96 |
| Immune Technology | IT-003-0012ΔTMp-1mg | HA(ΔTM)(H1N1) (A/Brisbane/59/2007) 1mg | 57402 |
| Immune Technology | IT-003-038Ep-0.1mg | M1(H3N2)(A/Brisbane/10/2007) | 7309.8 |
| Immune Technology | IT-003-039Ep-0.1mg | M1(A/Perth/16/2009)(H3N2) | 6282 |
| Immune Technology | IT-003-0012p-1mg | HA1(H1N1)(A/Brisbane/59/2007) 1mg | 57402 |
| Immune Technology | IT-003-0013p-1mg | HA1(H1N1)(A/WS/33) 1mg | 66792.96 |
| Immune Technology | IT-003-040Ep-0.1mg | M1 (A/California/07/2009)(H1N1) | 7309.8 |
| Immune Technology | IT-003-041Ep-0.1mg | M1 (B/Florida/4/2006) | 7309.8 |
| Immune Technology | IT-003-0014ΔTMp-1mg | HA(ΔTM)(A/South Carolina/1/18/(H1N1)) 1mg | 57402 |
| Immune Technology | IT-003-0014p-1mg | HA1(A/South Carolina/1/18(H1N1)) 1mg | 57402 |
| Immune Technology | IT-003-042Ep-0.1mg | M1 (B/Malaysia/2506/2004) | 6642 |
| Immune Technology | IT-003-043Ep-0.1mg | M1 (B/Yamagata/16/88) | 6282 |
| Immune Technology | IT-003-0015p-1mg | HA1(A/Bel/1942(H1N1)) 1mg | 66792.96 |
| Immune Technology | IT-003-0016p-1mg | HA1(A/USSR/92/77(H1N1)) 1mg | 57402 |
| Immune Technology | IT-003-045Ep-0.1mg | M1(H1N1)(A/Puerto Rico/8/1934) | 6282 |
| Immune Technology | IT-003-046Ep-0.1mg | NP(H1N1)(A/Puerto Rico/8/1934) | 6282 |
| Immune Technology | IT-003-0017p-1mg | HA1(A/Albany/12/1951(H1N1)) 1mg | 57402 |
| Immune Technology | IT-003-0018p-1mg | HA1(A/Phila/1935(H1N1)) 1mg | 57402 |
| Immune Technology | IT-003-047Ep-0.1mg | M1(H7N9)(A/Shanghai/2/2013) | 6282 |
| Immune Technology | IT-003-050p-0.1mg | HA1(A/flat-faced bat/Peru/033/2010)(H18N11) | 8982 |
| Immune Technology | IT-003-0019p-1mg | HA1(A/Memphis/1/1987(H1N1)) 1mg | 66792.96 |
| Immune Technology | IT-003-001ΔTMp-1mg | HA(ΔTM)(H1N1/A/New Caledonia/20/99) 1mg | 57402 |
| Immune Technology | IT-003-1011p-0.1mg | NA(A/Michigan/45/2015)(H1N1) | 10451.52 |
| Immune Technology | IT-003-101p-0.1mg | NA(A/New Caledonia/20/1999(H1N1)) | 8982 |
| Immune Technology | IT-003-001p-1mg | HA1(H1N1)(A/New Caledonia/20/99) 1mg | 66792.96 |
| Immune Technology | IT-003-001SW1p-1mg | HA1(H1N1)(A/swine/Belgium/1/1998) 1mg | 57402 |
| Immune Technology | IT-003-103p-0.1mg | NA(A/Wisconsin/67/2005(H3N2)) | 8982 |
| Immune Technology | IT-003-1051p-0.1mg | NA(A/Viet Nam/1203/2004(H5N1)) | 10451.52 |
| Immune Technology | IT-003-001SW2p-1mg | HA1(H1N2)(A/swine/Gent/7625/1999) 1mg | 66792.96 |
| Immune Technology | IT-003-105p-0.1mg | NA (A/Hubei/1/2010(H5N1) | 10451.52 |
| Immune Technology | IT-003-107p-0.1mg | NA(A/Shanghai/2/2013(H7N9)) | 10451.52 |
| Immune Technology | IT-003-0032ΔTMp-1mg | HA(ΔTM)(A/Japan/305/1957(H2N2)) 1mg | 57402 |
| Immune Technology | IT-003-003p-1mg | HA1 (H2N2)(A/Canada/720/05) 1mg | 57402 |
| Immune Technology | IT-003-B11ΔTMp-0.1mg | HA(B/Phuket/3073/2013) | 10451.52 |
| Immune Technology | IT-003-B10p-0.1mg | HA1(B/YAMANASHI/4/2012) | 8982 |
| Immune Technology | IT-003-00410∆TMp-1mg | H3(∆TM)(H3N2)(A/Johannesburg/33/94) 1mg | 57402 |
| Immune Technology | IT-003-00410p-1mg | HA1(H3N2)(A/Johannesburg/33/94) 1mg | 66792.96 |
| Immune Technology | IT-003-B12p-0.1mg | HA1(B/Texas/6/2011) | 8982 |
| Immune Technology | IT-003-B11p-0.1mg | HA(B/Phuket/3073/2013) | 10451.52 |
| Immune Technology | IT-003-00411∆TMp-1mg | H3(∆TM)(H3N2)(A/Beijing/32/92) 1mg | 57402 |
| Immune Technology | IT-003-00411p-1mg | HA1(H3N2)(A/Beijing/32/92) 1mg | 66792.96 |
| Immune Technology | IT-003-B15∆TMp-0.1mg | HA(∆TM)(B/Harbin/7/1994) | 8982 |
| Immune Technology | IT-003-B13p-0.1mg | HA1 (B/Hong Kong/05/1972) | 8982 |
| Immune Technology | IT-003-00412∆TMp-1mg | H3(∆TM)(H3N2)(A/Guizhou/54/89) 1mg | 66792.96 |
| Immune Technology | IT-003-00412p-1mg | HA1(H3N2)(A/Guizhou/54/89) 1mg | 57402 |
| Immune Technology | IT-003-B16p-0.1mg | HA1(B/Finland/139/2010) | 8982 |
| Immune Technology | IT-003-B17p-0.1mg | HA1(B/Bangladesh/5945/2009) | 10451.52 |
| Immune Technology | IT-003-00414∆TMp-1mg | H3(∆TM)(H3N2)(A/Christchurch/4/85) 1mg | 57402 |
| Immune Technology | IT-003-00414p-1mg | HA1(H3N2)(A/Christchurch/4/85) 1mg | 66792.96 |
| Immune Technology | IT-003-B18p-0.1mg | HA1(B/Hong Kong/259/2010) | 10451.52 |
| Immune Technology | IT-003-B19∆TMp-0.1mg | HA(∆TM)(B/Massachusetts/2/2012) | 10451.52 |
| Immune Technology | IT-003-00415∆TMp-1mg | H3(∆TM)(H3N2)(A/Mississippi/1/85) 1mg | 66792.96 |
| Immune Technology | IT-003-00415p-1mg | HA1(H3N2)(A/Mississippi/1/85) 1mg | 66792.96 |
| Immune Technology | IT-003-B19p-0.1mg | HA1(B/Massachusetts/2/2012) | 8982 |
| Immune Technology | IT-003-B20p-0.1mg | HA1(B/Texas/02/2013) | 8982 |
| Immune Technology | IT-003-00416∆TMp-1mg | H3(∆TM)(H3N2)(A/Philippines/2/82) 1mg | 66792.96 |
| Immune Technology | IT-003-00416p-1mg | HA1(H3N2)(A/Philippines/2/82) 1mg | 57402 |
| Immune Technology | IT-003-B21△TMP-0.1mg | HA(∆TM)(B/Colorado/06/2017) | 8982 |
| Immune Technology | IT-003-B21p-0.1mg | HA1(B/Colorado/06/2017) | 8982 |
| Immune Technology | IT-003-00417∆TMp-1mg | H3(∆TM)(H3N2)(A/Victoria/3/75) 1mg | 57402 |
| Immune Technology | IT-003-00417p-1mg | HA1(H3N2)(A/Victoria/3/75) 1mg | 57402 |
| Immune Technology | IT-003-B2ΔTMp-0.1mg | HA(ΔTM)(B/Florida/4/2006) | 10451.52 |
| Immune Technology | IT-003-B2p-0.1mg | HA1(B/Florida/4/2006) | 8982 |
| Immune Technology | IT-003-B3ΔTMp-Enquiry | HA(ΔTM)(B/Brisbane/60/2008) | 3141.72 |
| Immune Technology | IT-003-B3p-0.1mg | HA1(B/Brisbane/60/2008) | 8982 |
| Immune Technology | IT-003-B4p-0.1mg | HA(∆TM)(B/Yamagata/16/1988) | 10451.52 |
| Immune Technology | IT-003-B6p-0.1mg | HA(∆TM)(B/Victoria/2/87) | 8982 |
| Immune Technology | IT-003-00418∆TMp-1mg | H3(∆TM)(H3N2)(A/Hong Kong/8/68) 1mg | 57402 |
| Immune Technology | IT-003-00419∆TMp-1mg | H3(∆TM)(H3N2)(A/Texas/1/77) 1mg | 57402 |
| Immune Technology | IT-003-B7∆TMp-0.1mg | HA(∆TM)(B/Wisconsin/01/2010) | 8982 |
| Immune Technology | IT-003-00419p-1mg | HA1(H3N2)(A/Texas/1/77) 1mg | 57402 |
| Immune Technology | IT-003-0041ΔTMp-0.5mg | HA(ΔTM)(H3N2/Wisconsin/67/X-161/2005) 0.5mg | 59504.22 |
| Immune Technology | IT-003-B7p-0.1mg | HA1(B/Wisconsin/01/2010) | 10384.92 |
| Immune Technology | IT-003-0041p-1mg | HA(ΔTM)(H3N2/Wisconsin/67/X-161/2005) 1mg | 66368.16 |
| Immune Technology | IT-003-B8p-0.1mg | HA1(B/Wisconsin/01/2012) | 10451.52 |
| Immune Technology | IT-003-B9p-0.1mg | HA1(B/Athens/97/2012) | 8982 |
| Immune Technology | IT-003-NB1p-0.1mg | NA(B/Colorado/06/2017) | 10451.52 |
| Immune Technology | IT-003-SW10p-0.1mg | HA1(A/swine/Zhejiang/1/2007(H1N1)) | 8982 |
| Immune Technology | IT-003-SW11∆TMp-0.1mg | HA(∆TM)(A/Beijing/01/2009(H1N1)) | 8982 |
| Immune Technology | IT-003-00420∆TMp-1mg | H3(∆TM)(H3N2)(A/England/42/72) 1mg | 57402 |
| Immune Technology | IT-003-SW12ΔTMp-0.1mg | HA(∆TM)(A/California/07/2009(H1N1)) | 10451.52 |
| Immune Technology | IT-003-00420p-1mg | HA1(H3N2)(A/England/42/72) 1mg | 57402 |
| Immune Technology | IT-003-00421∆TMp-1mg | HA(∆TM)(H3N2)(A/VICTORIA/208/2009) 1mg | 57402 |
| Immune Technology | IT-003-SW12p-0.1mg | HA1(A/California/07/2009)(H1N1) | 10384.92 |
| Immune Technology | IT-003-SW13∆TMp-0.1mg | HA(∆TM)(A/Beijing/22808/2009(H1N1)) | 10384.92 |
| Immune Technology | IT-003-00421p-1mg | HA1(H3N2)(A/VICTORIA/210/2009) 1mg | 57402 |
| Immune Technology | IT-003-SW14∆TMp-0.1mg | HA(∆TM)(A/New York/06/2009(H1N1)) | 8982 |
| Immune Technology | IT-003-SW16∆TMp-0.1mg | HA(∆TM)(A/Texas/05/2009(H1N1)) | 10451.52 |
| Immune Technology | IT-003-SW1Hp-0.1mg | HA(Head Region)(A/Mexico/InDRE4114/2009(H1N1)) | 10384.92 |
| Immune Technology | IT-003-00422p-1mg | HA1(A/Kentucky/05/2011)(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-SW1ΔTMp-0.1mg | HA(ΔTM)(A/California/06/2009)(H1N1) | 8982 |
| Immune Technology | IT-003-SW1p-0.1mg | HA1(A/California/06/2009(H1N1)) | 8982 |
| Immune Technology | IT-003-00423∆TMp-100ml | HA(∆TM)(A/Victoria/361/2011) (H3N2) 100ml | 57402 |
| Immune Technology | IT-003-00423p-1mg | HA1(A/Victoria/361/2011)(H3N2) 1mg | 66792.96 |
| Immune Technology | IT-003-SW1P-FITC -0.05mg | FITC labeled HA1(A/California/06/2009(H1N1)) | 7182 |
| Immune Technology | IT-003-SW21Ep-0.1mg | NS1(A/California/04/2009(H1N1)) | 7263.18 |
| Immune Technology | IT-003-00424p-1mg | HA1(A/Chiang Rai/277/2011)(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-00425p-1mg | HA1(A/Brisbane/299/2011 )(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-00426p-1mg | HA1(A/Hawaii/22/2012)(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-SW21p-0.1mg | NS1(A/California/04/2009(H1N1)) | 8982 |
| Immune Technology | IT-003-SW23Ep-0.1mg | M1(A/California/04/2009(H1N1)) | 6282 |
| Immune Technology | IT-003-00427p-1mg | HA1(A/Texas/50/2012)(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-00428ΔTMp-1mg | HA(ΔTM)(H3N2)(A/Switzerland/9715293/2013) 1mg | 57402 |
| Immune Technology | IT-003-SW2ΔTMp-0.1mg | HA(ΔTM)(A/Ohio/01/2007(H1N1)) | 8982 |
| Immune Technology | IT-003-00428p-1mg | HA1(A/Switzerland/9715293/2013)(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-00429p-1mg | HA1(H3N2)(A/California/7/2004) 1mg | 57402 |
| Immune Technology | IT-003-SW3p-0.1mg | HA1(A/swine/Iowa/15/1930(H1N1) | 8982 |
| Immune Technology | IT-003-0042ΔTMp-1mg | HA(ΔTM)(H3N2)(A/Brisbane/10/2007) 1mg | 66792.96 |
| Immune Technology | IT-003-SW4p-0.1mg | HA1(A/swine/Wisconsin/2/1966(H1N1)) | 8982 |
| Immune Technology | IT-003-0042p-1mg | HA1(H3N2)(A/Brisbane/10/2007) 1mg | 57402 |
| Immune Technology | IT-003-SW5∆TMp-0.1mg | HA(∆TM)(A/NewJersey/8/1976)(H1N1) | 8982 |
| Immune Technology | IT-003-00430ΔTMp-0.5mg | HA(A/Hong Kong/4801/2014)(H3N2) 0.5mg | 58230 |
| Immune Technology | IT-003-SW5p-0.1mg | HA1(A/NewJersey/8/1976(H1N1)) | 8982 |
| Immune Technology | IT-003-00430p-1mg | HA1(A/Hong Kong/4801/2014)(H3N2) 1mg | 66368.16 |
| Immune Technology | IT-003-SW6p-0.1mg | HA1(A/Swine/Wisconsin/136/97(H1N1)) | 8982 |
| Immune Technology | IT-003-00431p-1mg | HA1(A/Beijing/353/1989)(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-00432p-1mg | HA1(A/Bangkok/1/1979)(H3N2) 1mg | 57402 |
| Immune Technology | IT-003-SW7p-0.1mg | HA1(A/swine/Belgium/1/83(H1N1)) | 10451.52 |
| Immune Technology | IT-003-SW8p-0.1mg | HA1(A/swine/England/WVL7/1992 (H1N1)) | 8982 |
| Immune Technology | IT-003-00433ΔTMp-0.5mg | HA(ΔTM)(A/NEW CALEDONIA/71/2014)(H3N2) 0.5mg | 67325.58 |
| Immune Technology | IT-003-SW9p-0.1mg | HA1(A/swine/Guangxi/13/2006(H1N2)) | 10451.52 |
| Immune Technology | IT-003-00434ΔTMp-1mg | HA(ΔTM)(A/Singapore/INFIMH-16-0019/2006)(H3N2) 1mg | 57402 |
| Immune Technology | IT-004-001Ep-0.1mg | Pre-S(HBV/Genotype B) | 7309.8 |
| Immune Technology | IT-003-00434p-1mg | HA1(A/Singapore/INFIMH-16-0019/2016)(H3N2) 1mg | 66792.96 |
| Immune Technology | IT-004-005p-0.1mg | E2 (HCV) | 8982 |
| Immune Technology | IT-004-006Ep-0.1mg | HBcAg(HBV)(ayr) | 7309.8 |
| Immune Technology | IT-004-007Ep-0.1mg | HBeAg (HBV)(adw) | 6282 |
| Immune Technology | IT-004-008Ep-0.1mg | X Protein (HBV) | 6282 |
| Immune Technology | IT-004-011Ep-0.1mg | VP1(HAV) | 6282 |
| Immune Technology | IT-003-0043ΔTMp-1mg | HA(ΔTM)(A/Aichi/2/1968(H3N2)) 1mg | 57402 |
| Immune Technology | IT-004-012Ep-0.1mg | VP3(HAV) | 7309.8 |
| Immune Technology | IT-003-0043p-1mg | HA1(A/Aichi/2/1968(H3N2)) 1mg | 66792.96 |
| Immune Technology | IT-003-0044ΔTMp-1mg | HA(∆TM)(H3N2/Wisconsin/15/2009) 1mg | 57402 |
| Immune Technology | IT-004-013Ep-0.1mg | VP4(HAV) | 6282 |
| Immune Technology | IT-004-016Ep-0.1mg | Pre-S(HBV/Genotype C) | 7263.18 |
| Immune Technology | IT-003-0045ΔTMp-1mg | HA(∆TM)(H3N2/Perth/16/2009) 1mg | 66792.96 |
| Immune Technology | IT-003-0045p-1mg | HA1(H3N2/Perth/16/2009) 1mg | 66792.96 |
| Immune Technology | IT-004-021Ep-0.1mg | HDVAg | 6282 |
| Immune Technology | IT-004-051Ep-0.1mg | P2C (HAV) | 6282 |
| Immune Technology | IT-003-0046∆TMp-1mg | H3(∆TM)(H3N2)(A/Fujian/411/02) 1mg | 57402 |
| Immune Technology | IT-004-052Ep-0.1mg | P2C-P3A (HAV) | 6282 |
| Immune Technology | IT-003-0046p-1mg | HA1(H3N2)(A/Fujian/411/02) 1mg | 57402 |
| Immune Technology | IT-004-053Ep-0.1mg | P2C-P3B (HAV) | 7309.8 |
| Immune Technology | IT-003-0047ΔTMp-1mg | H3(∆TM)(H3N2)(A/Panama/07/99) 1mg | 66792.96 |
| Immune Technology | IT-003-0047p-1mg | HA1(H3N2)(A/Panama/07/99) 1mg | 66792.96 |
| Immune Technology | IT-004-054Ep-0.1mg | P3C (HAV) | 7309.8 |
| Immune Technology | IT-004-055Ep-0.1mg | Core (HCV/Genotype-1) | 7309.8 |
| Immune Technology | IT-003-0048∆TMp-1mg | H3(∆TM)(H3N2)(A/Sydney/5/97) 1mg | 66792.96 |
| Immune Technology | IT-004-056Ep-0.1mg | Core (HCV/Genotype-1a) | 6282 |
| Immune Technology | IT-003-0048p-1mg | HA1(H3N2)(A/Sydney/5/97) 1mg | 57402 |
| Immune Technology | IT-004-057Ep-0.1mg | Core (HCV/Genotype-1b) | 7309.8 |
| Immune Technology | IT-004-058Ep-0.1mg | Core (HCV/Genotype-2a) | 6282 |
| Immune Technology | IT-003-0049∆TMp-1mg | H3(∆TM)(H3N2)(A/Wuhan/359/95) 1mg | 66792.96 |
| Immune Technology | IT-003-0049p-1mg | HA1(H3N2)(A/Wuhan/359/95) 1mg | 57402 |
| Immune Technology | IT-004-059Ep-0.1mg | Core (HCV/Genotype-2b) | 7309.8 |
| Immune Technology | IT-004-060Ep-0.1mg | Core (HCV/Genotype-3a) | 6282 |
| Immune Technology | IT-003-004ΔTMp-1mg | HA(∆TM) (H3N2)(Wyoming/3/03) 1mg | 57402 |
| Immune Technology | IT-003-004p-1mg | HA1 (H3N2)(A/Wyoming/3/03) 1mg | 57402 |
| Immune Technology | IT-004-061Ep-0.1mg | Core (HCV/Genotype-3b) | 7309.8 |
| Immune Technology | IT-003-004SW1p-1mg | HA1(A/Iowa/08/2011(H3N2)) 1mg | 57402 |
| Immune Technology | IT-003-004SW2p-1mg | HA1(A/Minnesota/09/2010(H3N2)) 1mg | 57402 |
| Immune Technology | IT-004-062Ep-0.1mg | Core (HCV/Genotype-4) | 7309.8 |
| Immune Technology | IT-004-063Ep-0.1mg | Core (HCV/Genotype-5) | 6282 |
| Immune Technology | IT-003-004SW4p-1mg | HA1(A/Pennsylvania/14/2010(H3N2)) 1mg | 57402 |
| Immune Technology | IT-003-004SW3p-1mg | HA1(A/Kansas/13/2009(H3N2)) 1mg | 57402 |
| Immune Technology | IT-004-064Ep-0.1mg | Core (HCV/Genotype-6a) | 7309.8 |
| Immune Technology | IT-004-065Ep-0.1mg | Core (HCV/Genotype-3/10) | 6282 |
| Immune Technology | IT-003-004SW6p-1mg | HA1(H3N2v) (A/Indiana/07/2012) 1mg | 57402 |
| Immune Technology | IT-003-004SW5p-1mg | HA1(A/Ontario/RV1273/2005(H3N2)) 1mg | 66792.96 |
| Immune Technology | IT-004-066Ep-0.1mg | NS3 (HCV/Genotype-1a/Con) | 6282 |
| Immune Technology | IT-004-067Ep-0.1mg | NS3 (HCV/Genotype-1b/Con) | 7309.8 |
| Immune Technology | IT-003-004SW7p-1mg | HA1(H3N2)(A/swine/Flanders/1/1998) 1mg | 66792.96 |
| Immune Technology | IT-003-00511p-1mg | HA (A/Egypt/2321-NAMRU3/2007 (H5N1)) 1mg | 57402 |
| Immune Technology | IT-004-068-2aEp-0.1mg | NS3 (HCV/Genotype-2a/Con) | 7309.8 |
| Immune Technology | IT-004-068Ep-0.1mg | NS3 (HCV/Genotype-1c) | 7309.8 |
| Immune Technology | IT-003-00512p-1mg | HA (A/Egypt/chicken/2253-1/2006 (H5N1)) 1mg | 57402 |
| Immune Technology | IT-003-00513p-1mg | HA (A/goose/Guiyang/337/2006 (H5N1)) 1mg | 66792.96 |
| Immune Technology | IT-004-069Ep-0.1mg | NS3 (HCV/Genotype-2b/Con) | 6282 |
| Immune Technology | IT-004-070Ep-0.1mg | NS3 (HCV/Genotype-2c) | 6282 |
| Immune Technology | IT-003-00514p-1mg | HA (A/Japanese white-eye/Hong Kong/1038/2006 (H5N1)) 1mg | 66792.96 |
| Immune Technology | IT-004-071-3aEp-0.1mg | NS3 (HCV/Genotype-3a/Con) | 6282 |
| Immune Technology | IT-004-071Ep-0.1mg | NS3 (HCV/Genotype-3) | 7309.8 |
| Immune Technology | IT-003-00515p-1mg | HA (A/Common magpie/Hong Kong/5052/2007(H5N1)) 1mg | 57402 |
| Immune Technology | IT-004-072Ep-0.1mg | NS3 (HCV/Genotype-4c) | 6282 |
| Immune Technology | IT-004-073Ep-0.1mg | NS3 (HCV/Genotype-5) | 7309.8 |
| Immune Technology | IT-003-00516p-1mg | HA (A/chicken/India/NIV33487/2006 (H5N1)) 1mg | 66792.96 |
| Immune Technology | IT-003-00517p-1mg | HA(∆TM)(A/Egypt/3300-NAMRU3/08(H5N1)) 1mg | 57402 |
| Immune Technology | IT-004-074Ep-0.1mg | NS3 (HCV/Genotype-5a) | 7309.8 |
| Immune Technology | IT-004-075Ep-0.1mg | NS3 (HCV/Genotype-6) | 6282 |
| Immune Technology | IT-003-00518p-1mg | HA(∆TM)(A/chicken/Vietnam/NCVD-016/08(H5N1)) 1mg | 57402 |
| Immune Technology | IT-003-00519∆TMp-1mg | HA(∆TM)(H5N1)(A/Hubei/1/2010) 1mg | 57402 |
| Immune Technology | IT-004-076Ep-0.1mg | NS3 (HCV/Genotype-6a/Con) | 6282 |
| Immune Technology | IT-004-077Ep-0.1mg | NS5 (HCV/Genotype-1) | 7309.8 |
| Immune Technology | IT-003-00519p-1mg | HA1(H5N1)(A/Hubei/1/2010) 1mg | 57402 |
| Immune Technology | IT-004-078Ep-0.1mg | NS5a (HCV/Genotype-1a/Con) | 7309.8 |
| Immune Technology | IT-004-079aEp-0.1mg | NS5a (HCV/Genotype-1b) | 7263.18 |
| Immune Technology | IT-003-0051p-1mg | H5(H5N1)(A/Vietnam/1203/2004) 1mg | 57402 |
| Immune Technology | IT-004-079Ep-0.1mg | NS5 (HCV/Genotype-1b) | 7309.8 |
| Immune Technology | IT-004-080Ep-0.1mg | NS5 (HCV/Genotype-2) | 6282 |
| Immune Technology | IT-003-00520∆TMp-1mg | HA(∆TM)(H5N1)(A/Egypt/N03072/2010) 1mg | 57402 |
| Immune Technology | IT-003-00520p-1mg | HA1(H5N1)(A/Egypt/N03072/2010) 1mg | 57402 |
| Immune Technology | IT-004-081Ep-0.1mg | NS5 (HCV/Genotype-2a) | 6282 |
| Immune Technology | IT-004-082Ep-0.1mg | NS5 (HCV/Genotype-2b) | 6282 |
| Immune Technology | IT-003-00521p-1mg | HA1 (A/chicken/Egypt/S3280D/2011)(H5N1) 1mg | 57402 |
| Immune Technology | IT-003-00522p-1mg | HA1(A/Indonesia/NIHRD11771/2011)(H5N1) 1mg | 66792.96 |
| Immune Technology | IT-004-083Ep-0.1mg | NS5 (HCV/Genotype-3) | 6282 |
| Immune Technology | IT-004-084Ep-0.1mg | NS5 (HCV/Genotype-3a) | 6282 |
| Immune Technology | IT-003-00523p-1mg | HA1 (A/chicken/Vietnam/NCVD-700/2011)(H5N1) 1mg | 66792.96 |
| Immune Technology | IT-003-00524p-1mg | HA1(A/Cambodia/V0401301/2011)(H5N1)) 1mg | 57402 |
| Immune Technology | IT-004-085Ep-0.1mg | NS5 (HCV/Genotype-3b) | 6282 |
| Immune Technology | IT-003-00525p-1mg | HA1(A/chicken/Bangladesh/11rs1984-30/2011)(H5N1) 1mg | 66792.96 |
| Immune Technology | IT-004-086Ep-0.1mg | NS5 (HCV/Genotype-4) | 6282 |
| Immune Technology | IT-003-00526p-1mg | HA1(A/Cambodia/R0405050/2007 (H5N1)) 1mg | 66368.16 |
| Immune Technology | IT-004-087Ep-0.1mg | NS5 (HCV/Genotype-5) | 6282 |
| Immune Technology | IT-004-088Ep-0.1mg | NS5 (HCV/Genotype-6) | 6282 |
| Immune Technology | IT-003-00527ΔTMp-1mg | HA(ΔTM)(H5N1)(A/chicken/Viet Nam/NCVD-03/2008) 1mg | 57402 |
| Immune Technology | IT-003-00527p-1mg | HA1(H5N1)(A/chicken/Viet Nam/NCVD-03/2008) 1mg | 57402 |
| Immune Technology | IT-004-089Ep-0.1mg | NS5 (HCV/Genotype-6a) | 6282 |
| Immune Technology | IT-004-090Ep-0.1mg | ORF2 (403-461 a.a.)(HEV/Burma) | 7309.8 |
| Immune Technology | IT-004-091aEp-0.1mg | ORF2 (451-617 a.a.)(HEV/Mexico) | 6282 |
| Immune Technology | IT-003-00528p-1mg | HA1(A/turkey/Germany-MV/R2472/2014)(H5N8) 1mg | 66792.96 |
| Immune Technology | IT-003-00529p-1mg | HA1(A/mallard/Korea/W452/2014)(H5N8) 1mg | 57402 |
| Immune Technology | IT-003-0052ΔTMp-1mg | HA(ΔTM)(A/Indonesia/5/2005(H5N1)) 1mg | 57402 |
| Immune Technology | IT-003-0052p-1mg | H5 (H5N1)(A/Indonesia/5/2005) 1mg | 57402 |
| Immune Technology | IT-003-00530p-1mg | HA1(A/environment/Hubei/950/2013)(H5N1) 1mg | 66368.16 |
| Immune Technology | IT-003-00531p-1mg | HA1(A/northern pintail/Washington/40964/2014)(H5N2) 1mg | 66792.96 |
| Immune Technology | IT-003-00532p-1mg | HA1(A/turkey/BC/FAV10/2014)(H5N2) 1mg | 57402 |
| Immune Technology | IT-004-091Ep-0.1mg | ORF2 (452-617 a.a.)(HEVBurma) | 7309.8 |
| Immune Technology | IT-004-092Ep-0.1mg | ORF2 (633-659 a.a.) (HEV) | 6282 |
| Immune Technology | IT-003-00533p-1mg | HA1(A/Sichuan/26221/2014)(H5N6) 1mg | 57402 |
| Immune Technology | IT-003-00534p-1mg | HA1(A/Guizhou/1/2013)(H5N1) 1mg | 66792.96 |
| Immune Technology | IT-003-00535p-1mg | HA1(A/chicken/Iowa/04-20/2015) (H5N2) 1mg | 66792.96 |
| Immune Technology | IT-003-00536p-1mg | HA1(A/tufted duck/Germany-SH/R8444/2016) (H5N8) 1mg | 57402 |
| Immune Technology | IT-004-093Ep-0.1mg | ORF3 (HEV/Burma) | 6282 |
| Immune Technology | IT-003-00537ΔTMp-1mg | HA(ΔTM)(A/common magpie/Hong Kong/5052/2007)(H5N1) 1mg | 57402 |
| Immune Technology | IT-004-094Ep-0.1mg | NS4 (HCV/Genotype-1a/Con) | 6282 |
| Immune Technology | IT-003-00538p-1mg | HA1 (A/Hubei/29578/2016)(H5N6) 1mg | 57402 |
| Immune Technology | IT-003-0053ΔTMp-1mg | HA(ΔTM)(A/Anhui/1/2005(H5N1)) 1mg | 57402 |
| Immune Technology | IT-004-095Ep-0.1mg | NS4 (HCV/Genotype-1b/Con) | 7309.8 |
| Immune Technology | IT-003-0053p-1mg | H5 (H5N1)(A/Anhui/1/2005) 1mg | 57402 |
| Immune Technology | IT-004-096Ep-0.1mg | NS4 (HCV/Genotype-2a/Con) | 6282 |
| Immune Technology | IT-003-00540p-1mg | HA1 (A/chicken/Ghana/20/2015(H5N1)) 1mg | 57402 |
| Immune Technology | IT-004-097Ep-0.1mg | NS4 (HCV/Genotype-2b/Con) | 6282 |
| Immune Technology | IT-003-0054p-1mg | HA (B/Malaysia/2506/2004) 1mg | 57402 |
| Immune Technology | IT-004-098Ep-0.1mg | NS4 (HCV/Genotype-3a/Con) | 6282 |
| Immune Technology | IT-003-0055p-1mg | HA (A/Bar-headed Goose/Qinghai/12/05) 1mg | 66792.96 |
| Immune Technology | IT-003-0056p-1mg | HA1(H5N1)(A/Hong Kong/156/97) 1mg | 66368.16 |
| Immune Technology | IT-004-102Ep-0.1mg | NS4 (HCV/Genotype-6a/Con) | 6282 |
| Immune Technology | IT-003-0057p-1mg | HA1(H5N1)(A/Hong Kong/483/97) 1mg | 66792.96 |
| Immune Technology | IT-004-TIM-1p-0.1mg | Human TIM-1 (Ectodomain) | 10451.52 |
| Immune Technology | IT-003-0058p-1mg | HA2(A/Vietnam/1203/2004)(H5N1) 1mg | 57402 |
| Immune Technology | IT-004-TIM-3p-0.1mg | Human TIM-3 (Ectodomain) | 8982 |
| Immune Technology | IT-003-0059p-1mg | HA1(H5N1)(A/Hong Kong/213/2003) 1mg | 57402 |
无锡药科美生物科技有限公司专业从事生命科学行业前沿技术服务与产品进出口服务，欢迎订购咨询全球各国各种进口产品。
